Monday, February 5, 2018

Treat the Pathway, not the Gene (from Precision Medicine and the Reinvention of Human Disease)

Treat the key pathway, not the genetic mutation (from Precision Medicine and the Reinvention of Human Disease)

Some of the earliest and most successful Precision Medication drugs have targeted specific mutations occurring in specific subsets of diseases. One such example is ivacaftor, which targets the G551D mutation present in about 4% of individuals with cystic fibrosis [135]. It is seldom wise to argue with success, but it must be mentioned that the cost of developing a new drug is about $5 billion [136]. To provide some perspective, $5 billion exceeds the total gross national product of many countries, including Sierra Leone, Swaziland, Suriname, Guyana, Liberia, and the Central African Republic. Many factors contribute to the development costs, but the most significant is the incredibly high failure rate of candidate drugs. About 95% of the experimental medicines that are studied in humans fail to be both effective and safe. The costs of drug development are reflected in the rising costs of drugs.

When a new drug is marketed to a very small population of affected individuals, the cost of treating an individual may be astronomical. Americans should not pin their hopes on the belief that one day, the FDA or CMS (which administrates Medicare) will step in and put a stop to the price rises. The Food and Drug Administration can approve or reject drugs, but it does not regulate prices. Likewise, Medicare is not permitted to consider cost when it decides whether a treatment can be covered. Knowing this, some notable pharmaceutical companies have raised the prices of medications far beyond their manufacturing costs [137–139]. In effect, the cost of curing curable diseases may exceed our ability to pay for those cures [139].

It is strongly in the interests of society to develop drugs that have the widest possible user market [140]. Drugs that target a mutation that is specific for a few individuals with a rare disease, or a tiny subpopulation of individuals who have a common disease, are highly problematic.

Our experiences with disease convergence teach us that clinical phenotypes are influenced by the activities of pathways and are seldom restricted to a specific mutation in a specific gene. We know this because rare diseases that exhibit locus heterogeneity affect different genes, but often target the same pathway. Likewise, acquired phenotypes of genetic diseases often involve inhibitors of the same key pathways that drive their genetic counterparts, without involving the protein product of the genetic form of the disease. We also know that the acquired version of most genetic diseases account for the bulk of disease occurrences. Therefore, if we want to develop treatments that benefit the greatest number of individuals affected by a disease, it would be far more practical to find treatments that target the disease-driving pathways than to design drugs that target a specific gene mutation involved in a small subset of affected patients.

Before closing, here are a few points worth considering (to be discussed in later blogs):

  • As a generalization, any drug that can block a pathway, without producing serious side effects, may serve as a candidate treatment for all of the diseases that are driven by the pathway.

  • Individuals in the early stages of common diseases, before multiple disease pathways converge to produce an intractable clinical phenotype, may be particularly amenable to treatments that interfere with the pathways that promote the ensuing steps in pathogenesis.

The topic of clinical trials designed to test drugs targeting convergent disease pathways is discussed in Precision Medicine and the Reinvention of Human Disease, Section 9.6, “Fast, Cheap, Precise Clinical Trials.”

- Jules Berman

key words: precision medicine, precision treatment, clinical trials, cost of precision medicine, pathways, convergent pathways, jules j berman Ph.D., M.D.

Sunday, February 4, 2018

National Patient Identifiers (from Precision Medicine and the Reinvention of Human Disease)

Readers from outside the United States are probably wondering why the United States agonizes over the problem of patient identification. In many other countries, individuals are given a unique national identifier, and all medical data associated with the individual is kept in a central data repository under the aegis of the government’s health service. A single, permanent identifier is used by a patient throughout life, in every encounter with a hospital, clinic, or private physician. As a resource for researchers, the national patient identifier ensures the completeness of data sets and eliminates many of the problems associated with poorly implemented local identifier systems.

In the United States, there has been fierce resistance to the idea of national patient identifiers. The call for a national patient identification system is raised from time to time. The benefits to patients and to society are many. Regardless, US citizens are reluctant to have an identifying number that is associated with a federally controlled electronic record of their private medical information. In part, this distrust results from the lack of any national insurance system in the United States. Most health insurance in the United States is private, and private insurers have wide discretion over the fees and services provided to enrollees. There is a fear that if there were a national patient identifier with centralized electronic medical records, insurers would withhold reimbursements or raise premiums or otherwise endanger the health of patients. Because the cost of US medical care is the highest in the world, medical bills for uninsured patients can quickly mount, impoverishing individuals and families.

Realistically, though, no data is safe. Medical records can be stolen, and governments can demand access to medical records, when necessary [See Lewin T. Texas orders health clinics to turn over patient data. The New York Times; October 23, 2015].

Life has its compromises. Everyone wants their privacy and we all get angry when we hear that our confidential information has been stolen. Data breaches today may involve hundreds of millions of confidential records. The majority of Americans have had social security numbers, credit card information, and private identifiers (e.g., birth dates, city of birth, names of relatives) misappropriated or stolen. It’s natural to object to anything that might jeopardize our privacy. Nonetheless, we must ask ourselves the following: “Is it rational to forfeit the very real opportunity of developing new safe and effective treatments for serious diseases, for the very small likelihood that someone will crack your deidentified research record and somehow leverage this information to your disadvantage?”

Suppose everyone in the United States were given a choice: you can be included in a national patient identifier system, or you can opt out. Most likely, there would be many millions of citizens who would opt out of the offer, seeing no particular advantage in having a national patient identifier, and sensing some potential harm. Now, suppose you were told that if you chose to opt out, you would not be permitted to use any of the therapeutic or preventive benefits that come from studies performed with data collected from the national patient identifier system. These lost benefits would include safe and effective drugs, warnings of emerging epidemics, information on side effects associated with your medications, biomarker tests for preventable illnesses, and so on. Those who made no effort to help the system would be barred from any of the benefits that the system provided. Would you reconsider your refusal to cooperate, if you knew the consequences? Of course, this is a fanciful scenario, but it makes a point.

- Jules Berman

key words: identification, confidentiality, privacy, medical identifier, NPI, national patient identifier, jules j berman, Ph.D., M.D.

Saturday, February 3, 2018

Paradoxes of Classification (and terrible Class definitions)

The formal systems that assign data objects to classes, and that relate classes to other classes, are known as ontologies. When the data within a Big Data resource is classified within an ontology, data analysts can determine whether observations on a single object will apply to other objects in the same class. Similarly, data analysts can begin to ask whether observations that hold true for a class of objects will relate to other classes of objects. Basically, ontologies help scientists fulfill one of their most important tasks; determining how things relate to other things.

A classification is a very simple form of ontology, in which each class is allowed to have only one parent class. To build a classification, the ontologist must do the following: 1) define classes (i.e., find the properties that define a class and extend to the subclasses of the class); 2) assign instances to classes; 3) position classes within the hierarchy; and 4) test and validate all the above.

The constructed classification becomes a hierarchy of data objects conforming to a set of principles:

  • The classes (groups with members) of the hierarchy have a set of properties or rules that extend to every member of the class and to all of the subclasses of the class, to the exclusion of unrelated classes . A subclass is itself a type of class wherein the members have the defining class properties of the parent class plus some additional property(ies) specific for the subclass.

  • In a hierarchical classification, each subclass may have no more than one parent class. The root (top) class has no parent class. The biological classification of living organisms is a hierarchical classification.
  • At the bottom of the hierarchy is the class instance. For example, your copy of this book is an instance of the class of objects known as "books".
  • Every instance belongs to exactly one class.
  • Instances and classes do not change their positions in the classification. As examples, a horse never transforms into a sheep, and a book never transforms into a harpsichord.
  • The members of classes may be highly similar to one another, but their similarities result from their membership in the same class (i.e., conforming to class properties), and not the other way around (i.e., similarity alone cannot define class inclusion).

Classifications are always simple; the parental classes of any instance of the classification can be traced as a simple, non-branched list, ascending through the class hierarchy. As an example, here is the lineage for the domestic horse (Equus caballus), from the classification of living organisms:

Equus caballus
Equus subg. Equus
Equus
Equidae
Perissodactyla
Laurasiatheria
Eutheria
Theria
Mammalia
Amniota
Tetrapoda
Sarcopterygii
Euteleostomi
Teleostomi
Gnathostomata
Vertebrata
Craniata
Chordata
Deuterostomia
Coelomata
Bilateria
Eumetazoa
Metazoa
Fungi/Metazoa group
Eukaryota
cellular organisms

Taxonomists who view this lineage instantly grasp the place of domestic horses in the classification of all living organisms.

The rules for constructing classifications seem obvious and simplistic. Surprisingly, the task of building a logical, and self-consistent classification is extremely difficult. Most classifications are rife with logical inconsistencies and paradoxes. Let's look at a few examples.

In 1975, while touring the Bethesda, Maryland campus of the National Institutes of Health, I was informed that their Building 10, was the largest all-brick building in the world, providing a home to over 7 million bricks . Soon thereafter, an ambitious construction project was undertaken to greatly expand the size of Building 10. When the work was finished, building 10 was no longer the largest all-brick building in the world. What happened? The builders used material other than brick, and Building 10 lost its classification as an all-brick building, violating the immutability rule of class assignments.

Apparent paradoxes that plague any formal conceptualization of classifications are not difficult to find. Let's look at a few more examples.

Consider the geometric class of ellipses; planar objects in which the sum of the distances to two focal points is constant. Class Circle is a child of Class Ellipse, for which the two focal points of instance members occupy the same position, in the center, producing a radius of constant size. Imagine that Class Ellipse is provided with a class method called "stretch", in which the foci are moved further apart, thus producing flatter objects. When the parent class "stretch" method is applied to members of the Class Circle, the circle stops being a circle and becomes an ordinary ellipse. Hence the inherited "stretch" method forces members of Class Circle to transition out of their assigned class, violating the intransitive rule of classifications.

Let's look at the "Bag" class of objects. A "Bag" is a collection of objects, and the Class Bag is included in most object-oriented programming languages. A "Set" is also a collection of objects (i.e., a subclass of Bag), with the special feature that duplicate instances are not permitted. For example, if Kansas is a member of the set of U.S. States, then you cannot add a second state named "Kansas" to the set. If Class Bag were to have an "increment" method, that added "1" to the total count of objects in the bag, whenever an object is added to Class Bag, then the "increment" method would be inherited by all of the subclasses of Class Bag, including Class Set. But Class Set cannot increase in size when duplicate items are added. Hence, inheritance creates a paradox in the Class Set.

How does a data scientist deal with class objects that disappear from their assigned class and reappear elsewhere? In the examples discussed here, we saw the following:

  1. Building 10 at NIH was defined as the largest all-brick building in the world. Strictly speaking, Building 10 was a structure, and it had a certain weight and dimensions, and it was constructed of brick. "Brick" is an attribute or property of buildings, and properties cannot form the basis of a class of building, if they are not a constant feature shared by all members of the class (i.e., some buildings have bricks; others do not). Had we not conceptualized an "all-brick" class of building, we would have avoided any confusion.

  2. Class Circle qualified as a member of Class Ellipse, because a circle can be imagined as an ellipse whose two focal points happen to occupy the same location. Had we defined Class Ellipse to specify that class members must have two separate focal points, we could have excluded circles from class Ellipse. Hence, we could have safely included the stretch method in Class Ellipse without creating a paradox.

  3. Class Set was made a subset of Class Bag, but the increment method of class Bag could not apply to Class Set. We created Class Set without taking into account the basic properties of Class Bag, which must apply to all its subclasses. Perhaps it would have been better if Class Set and Class Bag were created as children of Class Collection; each with its own set of properties.

Worst Class Definition Ever

The worst definition of a Class may have been that given to the Kingdom of Protozoa, defined as the class of one-celled eukaryotic organisms. The problem here is that all of the classes of multicelled organisms (e.g., animals, plants and fungi) descended from classes of one-celled organisms. This means that Class Protozoa (defined as one-cell organisms) must exclude from its lineage all descendant classes that are multicellular. Hence, Kingdom Protozoa was given a definition that, paradoxically, excluded its own descendants. What there they thinking, back in the mid-19th century when Class Protozoa was conceived?

- Jules Berman

key words: classification, ontology, taxonomy, paradoxes, precision medicine, jules j berman Ph.D., M.D.

Thursday, February 1, 2018

Precision Medicine and the Reinvention of Human Disease (not just about genes)

If everything you know about Precision Medicine comes from the lay press, you may have an unrealistic notion of what's happening in this field. The news seems to stress the one gene -> one disease paradigm that is easy to understand, but largely irrelevant to all the common diseases that occur in humans.

The one gene -> one disease paradigm is this: the clinical expression of each disease is caused by a genetic mutation in a particular gene responsible for that particular disease, or a particular subtype of a disease, in a particular individual. By finding and targeting the gene responsible for an individual's disease, Precision Medicine will cure the patient.

This paradigm is short and sweet, and it is more or less true for a number of rare diseases; but it is wrong for just about every disease that occurs commonly in humans, and it serves to distract our attention from the medical revolution that Precision Medicine will bring.

The purpose of my new book, Precision Medicine and the Reinvention of Human Disease, discussed in previous blogs, is to explain how Precision Medicine is changing our fundamental understanding of the pathogenesis of disease (i.e., the biological steps that lead to the development of diseases), and how this new information is changing the way that we prevent, diagnose, and treat human diseases.

Precision Medicine is not about finding the right gene for the right patient. Precision Medicine is about finding the common events and metabolic pathways that account for the development and the expression of diseases; and using these insights to reduce the morbidity and mortality of disease in the population.

Google Books has a very good "look inside" for my book, and I hope that readers of this blog will take a few moments to see if they might be interested in the subject.

- Jules Berman

key words: precision medicine, jules j berman, Ph.D., M.D., disease biology, pathogenetic, monogenic, rare diseases, complex diseases, common diseases

Sunday, January 28, 2018

Precision Medicine and the Reinvention of Human Disease (a better definition)

We can define Precision Medicine as an approach to the prevention, diagnosis, and treatment of disease that is based on a deep understanding of the sequence of biological events that lead to disease. With this approach we are learning:

(1) that we can develop new drugs that target specific steps in the development of disease;

(2) that drugs developed to interfere with a cellular event or pathway may serve as effective treatments for those individuals whose disease is driven by the pathway; and

(3) that a treatment effective for a subtype of one disease may also be effective against other diseases that happen to be driven by the same pathway.

This approach, based on learning the steps that precede the development of disease, shifts the emphasis of Precision Medicine from finding unique treatments for unique individuals to finding general treatments that are effective against precisely identified biological processes, in whichever diseases those processes may occur. In the era of Precision Medicine, every disease has a biological history, and every event in the history of the disease is a possible target for prevention, diagnosis, or treatment. At this point, we can begin to see the thread of a story that will unfold throughout my book, Precision Medicine and the Reinvention of Human Disease.

-Jules Berman

key words: precision medicine, definition, pathogenesis, steps in disease development, jules j berman

Saturday, January 27, 2018

Precision Medicine and the Reinvention of Human Disease (not just the genome)

If you believe the lay press, Precision Medicine involves sequencing a patient's genome and determining the proper treatment based on the individual's unique genetic attributes. The NIH (National Institutes of Health) seems to be encouraging this interpretation of the field. From the US National Institutes of Health comes the following description: "Precision Medicine is an emerging approach for disease prevention and treatment that takes into account people's individual variations in genes, environment, and lifestyle. The Precision Medicine Initiative will generate the scientific evidence needed to move the concept of Precision Medicine into clinical practice". An Advisory Committee to the NIH Director would include, under the mantle of Precision Medicine, "providing individual side-effect profiles of drugs, and preventative health care check-ups that include specific recommendations developed from interpreting an individual's genetic risk profile".

Between the millions of inter-individual variations in our genomes, the highly personalized lifestyle choices, and the differences in our environments, there seems to be plenty of uniqueness to spread around. It is easy to forget that our uniqueness as individuals often has much less to do with our diseases than does our sameness as members of the same species. Our sameness goes a long way toward explaining why humans seem to suffer from the same list of textbook diseases, regardless of their individualized genes and geography. Someone had to put the brakes on this epidemic of uniqueness.

Much to their credit, the National Research Council of the US National Academies tacked on the following caveat to the definition of Precision Medicine: "It does not literally mean the creation of drugs or medical devices that are unique to a patient, but rather the ability to classify individuals into subpopulations that differ in their susceptibility to a particular disease, in the biology and/or prognosis of those diseases they may develop, or in their response to a specific treatment". The Research Council wisely distinguished Personalized Medicine from Precision Medicine, by adding, "Although the term 'Personalized Medicine' is also used to convey this meaning, that term is sometimes misinterpreted as implying that unique treatments can be designed for each individual. For this reason, the Committee thinks that the term 'Precision Medicine' is preferable to 'Personalized Medicine'"

The National Research Council pointed out what should have been obvious from the start. We cannot provide individualized treatments, because treatments must be tested for safety and efficacy on groups of people. The best we can ever do is to assign patients to a group that has been fitted to a preapproved treatment. So where does this leave us?

More to follow in tomorrow's blog.

- Jules Berman

key words: precision medicine, genomics, individualized treatments, definition, jules j berman, Jules Berman Ph.D., M.D.

Friday, January 26, 2018

Precision Medicine and the Reinvention of Human Disease (from Preface)

Something has happened in the past two decades that has changed the way that modern biomedical scientist thinks about diseases. Because the changes in our perceptions have happened slowly, few of us have really taken notice of what it all means. The purpose of my latest book, Precision Medicine and the Reinvention of Human Disease, published January, 2018, is to show how advances in the field of Precision Medicine will forever change the way we understand and treat disease. Specifically, these advances are:

  • Diseases develop in steps. Modern methodology has enabled us to dissect the biological events and metabolic pathways that ultimately lead to the expression of disease. We can no longer think in terms of the "cause" of a disease, because most diseases have multiple contributory causes, that act over time. [Glossary Pathway]

  • Because disease development requires the successful completion of multiple, sequential steps, and because we can now observe some of these steps, Precision Medicine has given us multiple targets that we can attack, with the expectation of preventing diseases from developing, delaying the development of disease, or treating diseases that are driven by identifiable pathways.

  • Because different paths of development may lead to the same set of clinical findings, diseases can be subtyped into classes according to the specific pathways that drive their biology. Hence, treatment can be precisely targeted to subtypes of diseases that were formerly indistinguishable from one another.

  • Because diseases that appear to be unrelated might share biological pathways that can be successfully targeted by new classes of drugs, we can now prevent or treat a variety of diseases, using a drug that was specifically developed for one rare subtype of disease.

Precision Medicine and the Reinvention of Human Disease explains how we have come to believe that these four advances in Precision Medicine are true, and how these advances are impacting the practice of medicine.

- Jules Berman

key words: precision medicine, rare diseases, jules j berman, jules berman, pathogenesis

Thursday, January 25, 2018

Precision Medicine and the Reinvention of Human Disease (The Myth)

If you believe the hype, we are entering a new era of medicine in which each individual will receive unique treatment, determined by the sequence of his or her genome. This widely promulgated notion is simply ridiculous. There is no practical way to develop a unique treatment, test the treatment for safety and effectiveness, and titrate the correct dose, all for one person.

The terms "Precision Medicine" and "Personalized Medicine" have given us the false impression that medical science is moving away from off-the-rack remedies and is seeking treatments tailored to the individual. In actuality, science has always been about seeking generalization. When Isaac Newton watched an apple drop, he was not working on a new Law of Falling Apples. He was trying to understand the general laws of gravity and motion that applied to every object in the universe. When Charles Darwin spent 8 years studying barnacles, he was not trying to build a display collection of handsome barnacles for the national museum. He was developing a general theory of evolution that would apply to every living organism on earth. Likewise, when we study a specific pathway that is operative in a small percentage of cases of a rare tumor, accounting for perhaps a dozen patients worldwide, we expect that our findings will have general application to a wide variety of conditions.

Precision Medicine has very little to do with developing unique treatments. Like all medical research, Precision Medicine seeks to find general treatments that will be effective for the largest number of patients. The "Precision" in Precision Medicine refers to our ability to precisely diagnose rare diseases, and subsets of common diseases, that share a particular sensitivity to particular forms of treatment.

- Jules Berman

Tuesday, January 23, 2018

Precision Medicine and the Reinvention of Human Disease (Book Index)

In January, 2018, Academic Press published my book Precision Medicine and the Reinvention of Human Disease. This book has an excellent "look inside" at its Google book site, which includes the Table of Contents. In addition, I thought it might be helpful to see the topics listed in the Book's index. Note that page numbers followed by f indicate figures, t indicate tables, and ge indicate glossary terms.


A
Abandonware, 270, 310ge
Ab initio, 34, 48ge, 108ge
ABL (abelson leukemia) gene, 28, 58ge, 95–97
Absidia corymbifera, 218
Acanthameoba, 213
Acanthosis nigricans, 144ge
Achondroplasia, 74, 143ge, 354ge
Acne, 54ge, 198, 220ge
Acquired autoantibody disease, 133
Acquired Parkinsonism, 105ge, 128, 281
Acrodermatisis verruciformis, 26–27
Acrokeratosis verruciformis of Hopf, 23–24
Actinic keratoses, 33
Actinobacillus actinomycetemcomitans, 217
Actinomyces pyogenes, 217
Activated oncogene, 28, 34–35, 57ge, 222ge
Acute anterior uveitis, 208
Acute flaccid myelitis, 204–205
Acutely transforming retroviruses, 46–47
Acute myelogenous/myeloid leukemia, 33–34, 97, 139,
156–157
Adaptive immunity evolved, 192
Adenosine deaminase, 46, 72, 80
Adrenocortical carcinoma, 73, 103ge
Adult T-cell leukemia, 339
Adverse effect, 275, 352–353
Aflatoxin, 30, 182
  and hepatocellular carcinoma, 30, 182
Age adjusted incidence, 338, 354ge
Age related macular degeneration, 105ge, 138, 199
Aggregate disease, 80, 98ge
Aging, 35–36, 70–71, 125–126, 234, 354
Agouti, 86–87
AIRE gene, 198
Albinism, 77–78, 81–82, 84
Alcohol, 128, 156, 159, 287
  abuse, 128, 158
  related neurodevelopmental disorders, 159
Allele, 70, 98ge, 158–159, 332–333, 347–348
Allelic heterogeneity, 71, 98ge
Alpha1 antitrypsin deficiency, 82
Alpha particles, 166–167
Alpha-spectrin gene, 70
Alpha thalassemia, 83, 92
Alstrom syndrome, 122–123
Alternative RNA, 85, 98ge
Alzheimer disease, 6–7, 70, 139, 233–234, 246, 327–328, 353
Amateur scientists, 329–330
Aminoglycoside, 128
  induced hearing loss, 77
Amoebic encephalitides, 213
Amphotericin B, 128, 213
Amyloidosis, 83, 98ge, 200
Amyloid plaques, 126
Amyotrophic lateral sclerosis, 77, 282
Anaerobic conditions, 108ge
Anal squamous carcinoma, 45
Anaphylactic shock, 133
Anaphylaxis, 133
Anaplasma phagocytophilum, 217
Anatomic abnormalities, 6–7, 166–167
Ancestral class, 184, 231
Aneuploid, 89, 89f
Aneuploid cells, 49ge
Aneuploidy, 47, 89f
Angelman syndrome, 75, 86
Angiofollicular lymph node hyperplasia, 50ge
Angiogenesis, 120, 138
Angioimmunoblastic lymphadenopathy, 55ge
Angiopoietin, 139
Angiotensin converting enzyme inhibitors, 4
Animal model, 31, 33, 88, 170, 279, 351–354
Ankylosing spondylitis, 208
Anlagen, 243
Annotation, 264, 271, 308, 341
Anonymizing private and confidential medical data, 310
Anoxia, 91–92
Anterior segment mesenchymal dysgenesis, 53ge
Anthers, 90
Antibasement membrane antigen, 132
Antibiotics, 190, 195–196, 210, 213
Antibody/antibodies, 21–22, 73, 126, 130–134, 139, 192,
197, 209, 299, 348–350
Anticipation, 86
Anucleate ovum, 254ge
Anucleate red blood cell, 91
Aortic dissection, 142ge
Apicomplexans, 184, 186
Aplastic anemia, 24–25, 95–96, 166
Apolipoprotein E (APOE) gene, 70
Apoptosis, 48–61, 73, 133–134, 197–200
Archaeans, 191
Archaeplastida, 186, 191–192
Aromatase inhibitors, 136–137
Arrhythmias, 135
Arrhythmogenic right ventricular cardiomyopathy, 331
Arrhythmogenic right ventricular dysplasia, 70
Artemis gene, 72
Arteriosclerosis, 171
Arthritis, 131–132, 134, 139, 197–198, 201, 208, 346,
349–350
Arthropod vectors, 202
Arylsulfatase, 121–122
  deficiency, 121–122
Asbestos, 26–27, 29, 167–169, 279–280
Ash leaf spots, 102ge
Aspergillus flavus, 182
Aspergillus fumigatus, 214
Aspirin, 124, 135
Asplenia/polysplenia, 72
Ataxia, 73, 83, 91, 128, 159
telangiectasia, 91
Atherosclerosis, 158, 171, 199
Atrial myxomas, 95–96
Atrioventricular conduction defects, 53ge
ATRX gene, 92
Atypical hemolytic uremic syndrome, 199
Atypical intraductal hyperplasia, 32
Authentication, 273
Autism, 7, 138
Autoantibodies, 133–135, 137–138
Autoantibody disease, 130–134, 197
Autocoders, 283
Autocoding, 277, 282–283
Autocorrelation, 267
Autoimmune disease, 21–22, 131–134, 193, 197–198, 251
Autoimmune disorder characterized, 131
Autoimmune hemolytic anemia, 144ge
Autoimmune lymphoproliferative syndrome (ALPS),
133–134, 197–198
Autoimmune polyendocrinopathy-candidiasisectodermal
dystrophy, 198
Autoimmune thyroiditis, 201
Autoimmune variant, 73, 123–124
Autoinflammatory diseases, 197, 235
Autonomous growth, 46
Autophagy, 83
Autopsies, 81
Autopsy report, 36, 277
Autosomal dominant hearing loss, 104ge, 106ge
Autosomal dominant polycystic kidney disease, 122–123
Autumn crocus (Colchicum autumnale), 200
Axonal neuropathy, 70
Azacytidine, 87

B
Bacillary angiomatosis, 202, 210–211
Bacille Calmette-Guerin (BCG), 22–23
Bacillus
  B. globigii, 212
  B. hoagii, 218
Bacteremia, 202, 213
Bacteroides
  B. fragilis, 214
  B. vulgatus, 214
Bannayan-Riley-Ruvalcaba syndrome, 156, 173ge
Bardet-Biedl syndrome, 72, 122–123, 157
Barr body, 85–86
Bartonella
  B. henhenselae, 210–211
  B. quintana, 202, 217
Bartonella species, 202–203
Bartter syndrome, 136f
Basal body, 72
Basal cell carcinoma, 158, 170
Base pairs (bp), 84, 86
Bastocystis, 213
B cell, 161, 192, 339, 346, 349–350  
  acute lymphoblastic leukemia, 160–161
  lymphomas, 339, 349–350
BCR-ABL, 56ge
Bcr/abl fusion gene, 28, 95–97, 251
BCR (breakpoint cluster region) gene, 58ge
Beckwith-Wiedemann syndrome, 75, 86, 106ge
Behcet disease, 99ge, 206
Benign tumor, 26–27, 50ge, 176ge
Benzene, 166, 169
Bernard-Soulier syndrome, 59ge, 135
Bevacizumab, 138, 142ge
Bilateral acoustic schwannomas, 56ge
Bilateral progressive sensorineural hearing loss, 135
Bilateral retinoblastomas, 318ge
Biliary atresia, 122–123
Bimodal age distribution, 52ge, 104ge, 292–293
Biomarker development, 252
Birth defects, 159, 335
Bisphossy jaw, 168–169
Bite infections, 213
BK virus, 339
Bladder catheters, 214
Bladder tumor, 95
Blast cells, 104ge
Blastocystis, 213
Blast transformation, 104ge
Blastula, 3, 51ge, 85, 235, 255ge, 335–336, 356ge
Blau syndrome, 54ge, 199, 220ge
Blended class, 205–206, 218ge, 246, 252ge, 258ge
Blepharspasm, 350
Blistering disease, 123–124, 132
Blood cell lineages, 49ge
Blood cells, 28, 82, 91, 131, 133–134, 137, 139–140,
164–166, 172, 197–198, 281, 295, 328
Blood clotting cascade, 164
Bloom syndrome, 50ge
Boder sedgwick syndrome, 99ge
Bone marrow failure, 24–25
Bone marrow necrosis, 30
Bone marrow stem cells, 49ge
Bone marrow toxins, 166
Bootstrapping, 232, 287–288
Botox, 138, 171, 350
Bovine spongiform encephalitis, 219ge
Bovine spongiform encephalopathy, 144ge
BRAF, 290, 347–348
  mutation, 347–348
  V600E, 94–95
Brain tubers, 354
Branchiootorenal syndrome, 53ge
BRCA gene, 28, 119, 126
Breakpoint cluster region (BCR) gene, 58ge
Breast cancer, 32, 32f, 73–74, 95, 119, 126, 136–137, 250,
252, 299, 338, 347–348, 352
Bronchiectasis, 123, 289
Bronchioloalveolar carcinoma, 173ge
Bronchoalveolar carcinoma, 173ge
Bronchogenic carcinoma, 169
Bronchogenic lung cancer, 159, 167
Brucellosis, 200
Bruck syndrome, 142ge
Brugada syndrome, 142ge
Brugia malayi, 223ge
Buerger disease, 159
Burgess shale reserves provided, 343
Burkitt lymphoma, 45, 161, 251, 339
Bypassing trials, 349

C
Caffey disease (infantile cortical hyperostosis), 142ge
CAG repeat, 71–72, 108ge, 300
Campylobacter pylori, 217
Cancer
  chemotherapy, 105ge, 157
  death rate, 161, 245, 345
  deaths, 31, 161, 167, 182, 245, 338, 340, 345
  phenotype, 9ge, 46–47, 49ge
  progression, 87, 99ge
Cancer-causing syndrome, 50ge
Candidate biomarkers, 252
Candidate causal mutations, 94
Candidate gene, 79, 99ge, 129, 303, 331
  approach, 99ge
Carbapenem resistant Klebsiella pneumoniae,
38–40
Carcinogen, 29–31, 35, 50ge, 167, 169, 175ge, 182,
243, 347
Carcinogenesis, 9ge, 26–27, 30–31, 41, 46–47, 49–50ge,
54ge, 58ge, 73, 88–89, 167, 175ge, 338, 347
Carcinoid syndrome, 142ge, 144ge
Cardiac conduction, 164
Cardiac rhabdomyoma, 102ge
Cardiofaciocutaneous syndrome, 347–348
Cardiomyopathy, 101ge, 104ge, 128, 137, 209, 247–248,
331
Cargo disorder, 175ge
Cargo receptor complex, 100ge
Cargo vesicle, 100ge
Carney complex, 95–96, 99ge, 103ge
Carney syndrome, 50ge, 99ge
Carotid body chemoreceptor cells, 81
Carriers, 28, 32–33, 50ge, 78, 96–97, 107ge, 182, 194–195,
219ge, 332–336, 339
Case studies, 99ge
Castleman disease, 45, 50ge, 331
Categorical data, 291
Catheter, 214, 219ge
Cattle, 332–333
Causality, 6, 17–61, 356–357ge
  paradoxes, 17–25
Cause of death error, 311ge
CCR5 coreceptor, 172
Cd1a, 139
CD20 inhibitors, 346, 349–350
Ceased and liver tumor, 47
Celiac disease, 208
Cell death, 3, 48, 49ge, 61ge, 80, 91, 99ge, 133–134, 197–198,
254ge
Cell death rates, 254ge
Cell division, 3, 21, 56–58ge, 60–61ge, 90, 190–191
Cell free media, 203
Cell junctions, 193
Cell suicide, 48, 49ge
Cell type, 9ge, 19–20, 26, 30–31, 35, 42–43, 48, 49ge,
51–52ge, 56–58ge, 60ge, 71, 80, 84–85, 89–90, 92,
101ge, 107–108ge, 120, 129–130, 175ge, 219ge, 222ge,
278, 281
Cellular differentiation, 89, 100–101ge
Cellular hypoxia, 81
Cellular pathway, 4, 120, 128–130, 164, 169–170, 175ge,
199
Cellulitis, 29, 213
Centers for Disease Control and Prevention (CDC),
38–40, 306–307
Cerebellar ataxia, 99ge, 128
Cerebellum, 102–103ge, 156, 159, 174ge
Cerebrospinal fluid, 79
Cervical cancer, 32, 338–340, 358ge
Chagas disease, 187–188, 194–195, 219ge, 339
Channel defects, 121
Channel disorders, 142ge
Channelopathies, 9–10ge, 124, 142ge
Charcot-Marie-Tooth disease, 51–52ge, 70, 175ge, 331
Chediak-Higashi syndrome, 10ge, 199
Chemodectomas, 81
Chemokine, 76, 100ge, 172
Chemoreceptor cell hyperplasia, 81
Chernobyl, 169
Cherubism, 199
Chicago heat wave, 295–296
Chikungunya virus, 219ge, 223ge
Childhood cancer, 27, 49ge, 161, 343, 345
Childhood thyroid cancer, 169
Chimeric Antigen Receptor for T cells (CAR-T) therapy,
161–162
Chimeric receptor, 161–162
Chimney sweeps, 166
Chimpanzee’s genome, 75–76
Chitin, 217, 242
Chlamydia trachomatis, 208
Chloramphenicol, 166
Chloroplasts, 191–192, 219ge
Cholangiocarcinoma, 30, 60ge, 166–167, 339
Chorioadenoma destruens, 255ge
Choriocarcinoma, 108ge, 161, 220ge, 251, 254–255ge,
257–258ge
Chromatin remodeling complex, 85, 89
Chromosomal aberration, 156–157
Chromosomal anomalies, 94, 335
Chromosomal instability, 49ge
Chronic myelocytic leukemia, 58ge, 161
Chronic myelomonocytic leukemia, 56ge, 104ge
Chronic obstructive pulmonary disease (COPD), 98ge,
158–159, 246, 253ge
Chronic recurrent multifocal osteomyelitis/synovitis,
198
Chryseobacterium meningosepticum, 217
Churg-Strauss syndrome, 206
Chytrids, 241–242
Cigarette smoking, 156, 173ge
Cigarette use, 158
Ciliated epithelia, 9ge
Ciliopathies, 9ge, 122–123, 124f
Circulating proteases, 82
Cirrhosis, 58ge, 82–83, 100ge, 126, 128–130, 158–159,
164–165t, 197
Cis acting, 100ge, 108ge
CJD prion, 144ge
C-KIT, 56ge, 103ge, 140
Clade, 253ge
Cladistics, 253ge, 255ge
Class Apicomplexa, 184
Class Archaeplastida, 191–192
Class assignment, 187, 205, 218ge, 221–222ge, 243–244,
252–253ge, 311ge
Class blending, 218ge, 244–247, 252ge
Class Crianata, 219ge
Classification, 5, 10ge, 59–60ge, 93–109, 183–184, 185f,
186–187, 206, 229–232, 239–244, 253ge, 269, 311ge,
341
Classifier algorithms, 243–244, 253ge
Class Mimiviridae, 221ge
Class properties, 184, 189, 231, 234–235, 256ge
Clear cell carcinoma, 106ge
Clinical trial, 5, 8ge, 136–137, 162, 239, 244, 295, 343–350
Clinorchis sinensis, 60ge
Clonal disorder, 105ge
Clonal expansion, 31, 56ge, 102ge, 105ge, 107ge, 134,
248–249
Cluster analysis, 253ge
Clustered Regularly Interspaced Short Palindromic
  Repeats (CRISPR) technology, 335–336
Coagulopathies, 235
Coding
  mutations, 99ge, 119, 126, 137, 140, 158–159, 281
  regions, 158–159
Codon, 56ge, 106ge, 287–288, 311ge
Coelomic, 237, 243
Colchicine, 200
Collagen disorder, 142ge
Collagenopathy, 128, 142ge, 164
Combined DNA Index System (CODIS), 265
Commensal organism, 214
Common ancestor, 102ge, 105ge, 187, 221–222ge
Comparing genome sequences, 265
Complement disorders, 199
Complement regulatory diseases, 198
Completeness, 230, 272, 276
Complex disease, 54ge, 58ge, 173ge, 201, 220ge, 352
Complexity barrier, 299–300
Conduction disorders, 164
Congenital anomaly, 51ge, 94, 355ge
Congenital disorder, 24–25, 51ge, 58ge, 164, 173ge, 175ge
Congenital dyserythropoietic anemia, 254ge
Congenital heart defects, 122–123
Congenital hyperinsulinism, 142ge
Congenital tumor, 155–156
Conserved gene variants, 157–158
Contig disease, 355ge
Contiguous gene deletion syndrome, 355ge
Control population, 298, 358ge
Control samples, 174ge
Control subjects, 99ge, 281
Converged pathway, 137, 140, 239
Convergence, 4–5, 8ge, 73–74, 117–145, 187, 200,
221–222ge
Convergent disease, 135–145, 340, 346, 350
COPD. See Chronic obstructive pulmonary disease
(COPD)
Copy neutral, 109ge
Copy number, 47, 51ge, 57ge, 102ge, 222ge
Coronary artery disease, 38, 143ge, 182
Coronary artery thrombosis, 38
Corpora amylacea, 126
Corpus callosum, 159
  and alcoholism, 159
Correlation, 96, 107ge, 121, 267, 315ge, 352
  distance, 311ge
Cost of curing curable disease, 141
Cowden syndrome, 50ge, 95, 100ge, 102ge, 156,
173–174ge
Cowdry bodies, 280f, 281
Coxsackie virus, 209
CpG islands, 84, 87, 100ge, 109ge
CpG methylation patterns, 100ge
CpG sites, 84, 90, 100ge
Cranioectodermal dysplasia (Sensenbrenner syndrome),
122–123
Creutzfeldt-Jakob disease, 144ge, 219ge
Cri du Chat, 104ge
CRISPR technology. See Clustered Regularly Interspaced
Short Palindromic Repeats (CRISPR) technology
Crohn disease, 54ge, 99ge, 199, 201, 220ge
Curator, 302, 307–308, 311ge
Curse of dimensionality, 296, 311ge
Cutis laxa, 72, 134, 289, 354ge
Cyanobacteria, 191–192, 219ge
Cyclooxygenase–2, 24
Cyclospora, 184, 219ge
Cyst, 104ge, 213, 216–217
Cystic fibrosis, 71, 98ge, 141, 142ge, 160, 334, 351, 356ge
Cytokine signaling, 83, 198
disorders, 199
Cytokine storm, 140, 352–353
Cytomegalovirus, 182, 222ge, 281
infection, 280f
Cytotoxic agents, 87, 105ge
Cytotoxic lymphocytes, 143ge
Cytotrophoblasts, 193, 238

D
DARC, 172
Darier disease, 24, 26–27
Dark data, 311ge
Data
  mining, 230, 355ge
  object, 9–10ge, 13ge, 143ge, 243–244, 253–258ge,
  264–271, 273–275, 285–286, 290–291, 298,
  311–314ge, 316–318ge, 355ge, 357–358ge
  readers, 341
  repurposing, 312ge, 355ge
  resource, 122–123, 252, 254ge, 271–272, 284, 286,
  292–293, 341, 352
  scrubbing, 307, 312ge, 355–356ge
  sharing, 302–318, 312ge, 343, 349
  triple, 267
Death certificate, 13ge, 38–40, 39f, 311ge, 339
Dedifferentiation, 101ge
Deficiency of the interleukin-1 receptor antagonist, 198
Deidentified record, 275, 308
Dengue virus, 223ge
De novo mosaic disease, 336
De novo mutation, 12ge, 24, 51ge, 57ge, 101ge, 107ge,
331–332, 334–336, 356ge
Dentatorubropallidoluysian atrophy, 108ge
Deoxyadenosine deaminase deficiency, 80
Deoxycoformycin, 80
Dermal bone, 254–255ge
Dermatofibroma, 45
Developmental disorder, 7, 75, 105ge, 139, 154–155t, 156
Diagnostic and Statistical Manual of Mental Disorders
(DSM), 7–13
Diethylstilbestrol fulfill, 30–31
Differentiation, 55ge, 80, 89, 100–101ge, 108ge, 243,
349–350
Digenic disease, 105ge, 173ge
DiGeorge syndrome, 104ge, 131
Dilated cardiomyopathy, 70, 95, 122–123, 128, 143ge
Dimensionality, 253ge, 296, 312ge, 356ge
Discordant diagnoses, 247–248
Disease convergence, 4–5, 8ge, 73, 117–145, 187, 200,
221–222ge
Disease pathway, 3, 40–44, 105ge, 142–145, 163, 170,
349–350, 353
Diseases-in-waiting, 205–210
Disease variants, 73, 78, 123–124, 132, 303, 331–332
Distal myopathy, 98ge, 279
Diuretics, 121, 136
DNA crosslink repair, 42, 51ge
DNA repair, 22, 34, 41–42, 48, 49ge, 51ge, 61ge, 72, 80, 84,
91, 99ge, 144ge, 164
DNA replication, 51ge, 144ge
Donovania granulomatis, 217
Double stranded DNA, 186–187, 221ge
Down syndrome, 52ge
Dravet syndrome, 142ge, 303
Driver pathway, 9ge, 170, 174ge
Drug-induced methemoglobinemia, 128
DSM. See Diagnostic and Statistical Manual of Mental
Disorders (DSM)
Ductal carcinoma in situ (DCIS), 32, 32f, 95
Duffy blood group antigen, 172
Dynein arms, 123
Dyserythropoiesis, 250, 254ge
Dyslipidemias, 164, 172
Dysmorphic facial development, 33–34
Dysmorphism, 121–122, 127, 156, 170, 234
Dysplasia, 51ge, 53ge, 70, 104ge, 122–123, 136f, 156–157,
175ge, 358ge
Dysplastic gangliocytoma, 102ge, 156
Dysplastic nevi, 33, 95
Dysregulations, 88, 106ge, 235
Dystrophic epidermolysis bullosa, 134
Dystrophin, 122

E
Early detection, 248–249, 251–252
Eaton lambert syndrome, 144ge
Ebola virus, 210
Ectoderm, 58ge, 61ge, 88, 101–102ge, 104ge, 235–238, 255ge
Edematous placental villi, 220ge
Eearly onset sarcoidosis, 54ge, 220ge
Ehlers-Danlos syndrome, 142ge
Electronic health record, 341
Electronic medical record, 272–273, 276, 340
Ellis van Creveld syndrome, 122–123
Embryo, 3, 30–31, 34, 54ge, 59ge, 85, 92, 103ge, 107ge, 235,
238, 252, 254–255ge
Embryogenesis, 81, 86, 103ge, 255ge
Embryonal carcinoma, 161, 238, 255ge
Emery-Dreifuss muscular dystrophy, 330
Emphysema, 82–83, 134, 158–159, 164–165t
Encapsulation, 308, 310, 312ge
Encephalitis lethargica, 206
Encephalitozoon intestinalis, 217
Enchondral bone, 238, 254–255ge
Encryption, 276, 312ge
Endocarditis, 202–203, 213, 220ge
Endoderm, 58ge, 61ge, 101ge, 104ge, 142ge, 235–238, 252ge,
255ge
Endodermal/Ectodermal neoplasms, 236
Endometrial carcinoma, 156
Environmental disease, 22, 83, 208
Environmental factors, 11–12ge, 24, 97, 119, 121, 127, 129,
158, 173, 173ge
Eosinophilic granulomatosis, 206
Epidermis, 30, 48, 53ge, 58ge, 60ge, 73, 101ge, 107ge,
123–124, 132, 242
Epidermolysis bullosa, 8ge, 70, 73, 123–124, 134
Epigenetic instability, 87, 108ge
Epigenome, 47–48, 51ge, 84–93, 89f, 100–101ge, 103ge,
108ge, 130, 154–155t
Epigenomic disease, 85, 90, 92
Epigenomics, 47–48, 84–93, 100–101ge, 129–130,
154–155t, 252ge
Epistasis, 6, 9ge, 42–43, 57ge, 144ge
Epithelial and non-epithelial tumors, 243
Eponymous disease, 45, 52ge
Epstein-Barr virus, 45, 55ge, 79, 140, 251, 339
Erasure, 85, 91, 103ge
Esophageal cancer, 159
ETV6-NTRK3 fusion, 250
Eugenics, 19, 331–337
Eukaryote, 55ge, 57ge, 182–183, 191–192, 205, 213, 219ge,
241, 354
Evolution, 48, 190–193, 230–231, 327–328, 343, 354
Evolutionary taxonomy, 184
Evolve, 8ge, 41–42, 60ge, 191–192, 306
Exceptional responders, 275, 295, 348–349
Exceptional responder trials, 348
Exome sequencing, 78–79, 98
Exon, 98ge, 101ge, 106ge
Exotic disease, 181, 219ge
Expressed genes, 109ge, 292
eXtended Markup Language (XML), 264–265, 317ge
EYA4 gene, 95

F
Facial angiofibromas, 102ge
Factor VIII, 56ge, 100ge, 134, 172
Facultative intracellular organism, 190–191, 220ge
Fair use, 307, 312ge
Familial aneurysm disorders, 142ge
Familial cold autoinflammatory syndrome, 54ge,
198–199, 220ge
Familial cold autoinflammatory syndrome-2
  (Guadaloupe periodic fever), 199
Familial dilated cardiomyopathy, 70, 95
Familial HLH, 199
Familial hypercholesterolemia, 56ge, 59ge, 164–165t, 171
Familial hypocalciuric hypercalcemia type, 134
Familial mediterranean fever, 54ge, 198, 200, 220ge
Fanconi anemia, 42, 49–51ge
Father’s sperm, 11ge
Ferruginous bodies, 279–280
Fibrochondrogenesis, 70
Fibromyalgia, 206
Fibrosing disorders, 199
Fibulin, 72
Filaria, 208, 218
First analyses, 303, 310
Flagellum, 199, 241–242
Flattening, 48, 341, 354
Flawed data, 307–308
Fleas, 202
Flu epidemic, 294, 332–333
Fluke, 48, 182, 339
Folic acid supplementation, 121
Food and Drug Administration, 141, 160–161, 346
Foreign antigen, 21–22, 192, 218ge
Forme fruste, 165, 174ge
Founder effect, 332–333, 356ge
Founder’s mutation, 356ge
Fourier series, 288, 357ge
Fragile x syndrome, 99ge, 108ge, 355ge
Free-lance data analysts, 343
Frequency, 34–36, 40, 57–58ge, 106–107ge, 125–127, 131,
155, 170, 189, 291, 292f, 300, 310, 318ge, 357ge
distribution, 291
Freshwater, 194
Friedreich ataxia, 83, 99ge, 108ge, 143ge
Frontotemporal dementia, 77, 281, 354ge
Fungemia, 212

G
GAA repeat, 83
Gain-of-function, 119
Gamete, 102–103ge, 174ge, 238, 255ge, 336
Gastric maltomas, 49ge
Gastrointestinal stromal tumor (GIST), 103ge, 140
Gastrulation, 236–238
Gaucher disease, 280, 334
Gaussian curve, 358ge
Gaussian distribution, 288, 291
Gene duplication, 105ge
Gene editing, 327–328, 335–336
Gene pool, 18, 35–36, 119, 157–158, 183–184, 190–191,
331–336
Gene sequence, 42, 161, 187, 204–205, 290
Gene silencing, 86–87, 336
Gene therapy, 46, 160–161
Genetically engineered mouse (GEM), 52ge
Genetic disease, 11ge, 22, 69–70, 120, 160, 208, 235, 335
Genetic heterogeneity, 8ge, 71, 74, 101ge, 103ge, 144ge
Genetic instability, 47, 49ge, 87–88, 89f, 92–93, 95, 99ge,
102ge, 175ge, 357ge
Genetic mosaicisms, 336
Genetic mutation, 2, 7ge, 11ge, 24–25, 72, 74–75, 80, 85, 90,
97, 118, 125, 127, 139, 145ge, 171, 175ge, 303
Genetic testing, 71
Genome testing, 97
Genome-wide Association Study (GWAS), 174ge
Genotype, 9ge, 23, 52ge, 60ge, 97, 99ge, 103ge, 144ge, 157,
175ge, 183, 215
Geriatric disease, 233
Germ cell(s), 52ge, 55–57ge, 59ge, 61ge, 102–103ge, 107ge,
155–156, 174–175ge, 235, 238, 251, 255ge, 290, 336,
339
  of body, 52ge
  line, 255ge, 336
  neoplasms, 238
  origin, 238, 290
  tumors, 103ge, 155–156, 238, 251, 339
Germinomas and seminomas, 175ge, 238, 255ge
Germ layer, 85, 104ge, 236–238, 242–243
Germline, 7ge, 25, 27–28, 33–34, 49ge, 51–52ge, 54ge, 60ge,
75–76, 80–82, 85–86, 97, 101ge, 103ge, 107ge, 109ge,
119, 126, 128, 130, 156, 220ge, 255ge, 313ge, 335–336
Germline mutation, 7ge, 25, 27, 33–34, 49ge, 51–52ge,
75–76, 80–82, 102ge, 107ge, 119, 130, 156
Gerstmann Straussler Scheinker Syndrome (GSS), 144ge
Gestational mole, 220ge
Gestational trophoblastic disease, 255ge
Giant cell (temporal) arteritis, 206
Gilbert syndrome, 57ge
GIST. See Gastrointestinal stromal tumor (GIST)
Glioblastoma, 138, 156
Gluten sensitive idiopathic neuropathies, 206
Glycosylation disorder, 58ge, 164, 173ge, 175ge
Gnathostomes, 192–193, 218ge
Golgi bodies, 41
Goodpasture syndrome, 132–133
Gorlin syndrome, 170, 175ge
Gout, 124, 198–201, 351–352
Granulocyte/macrophage colony stimulating factor
(GM-CSF), 137–138, 346
Graves’ disease, 131–132
Grawitz tumor, 282–283
Griscelli syndrome, 175ge, 199
Group A streptococcus infection, 21–22, 203
Gulf War syndrome, 206
GWAS. See Genome-wide Association Study (GWAS)

H
HACEK, 203, 213, 220ge
Haemophagocytic lymphohistiocytosis, 140, 199
Hairy cell leukemia, 55ge, 161
Hallermann Streiff syndrome, 206
Hamartin, 72, 103ge, 139, 354ge
Hamartoma, 56ge, 72, 100ge, 102ge, 138–139, 156, 174ge,
234, 354
Haploid, 86, 102ge
human genome, 287
Haploinsufficiency, 75
Haplotype, 86, 102ge
Hashimoto thyroiditis, 134
Healthcare institutions, 316ge
Hearing loss, 70, 82, 104ge, 106ge, 123, 128, 135,
173ge
Heat related deaths, 295–296
Heavy legs, 206
Helicobactor pylori infection, 49ge
Hematopoietic tissue, 166, 254ge
Hemochromatosis, 128, 143ge
Hemoglobin, 42, 56ge, 105ge, 107ge, 119, 143ge, 160, 163,
195–196, 334–335, 354ge
synthesis, 195–196
Hemolytic anemia, 133–134, 144ge, 197–198
Hemolytic uremic syndrome, 135, 199
Hemophagocytic lymphohistiocytosis, 99, 199
Hemophilias, 164, 235
HEMPAS, 254ge
Henoch schonlein purpura, 206
Hepatic angiosarcoma, 166–167
Hepatitis B virus, 339–340
Hepatitis C virus, 339
Hepatocellular carcinoma, 30, 47, 52ge, 58ge, 83, 166–167,
182, 339–340
Herceptin, 348
Hereditary angioedema, 126, 135
Hereditary hemorrhagic telangiectasia, 138
Hereditary inclusion body myopathy, 98ge
Hereditary leiomyomatosis, 79
Hereditary nonpolyposis colorectal cancer syndrome
(HNPCC), 143ge
Hereditary thrombocythemia, 98ge, 105ge, 139, 165
Hermansky-Pudlak syndrome, 175ge, 199
Herpes simplex infections, 194–195, 281
Heterochromasia iridum, 289
Heterokont, 213
Heterotaxy, 72, 105ge, 123
Heterozygosity, 54ge, 103ge, 109ge
High blood pressure, 44, 136
Hispaniola, 189, 196
Histiocytic medullary reticulosis, 103ge
HIV, 100ge, 128, 172, 196, 199, 221ge
and AIDS, 210–211, 219ge
Hodgkin lymphoma, 45, 52ge, 70, 161, 292–293, 293f,
357ge
Holt-Oram syndrome, 61ge, 76, 145ge
Homolog 1, 130
Homologous genes, 184
Homologs, 105ge, 354
Homology, 214, 253ge
Homunculus, 3
HTLV-1, 339
HTT gene (and CAG repeat), 71–72
Human malaria, 215
Human subject, 275–276, 294–295, 301, 307–308, 310,
345–346, 348, 356ge
Huntingtin protein, 71–72
Huntington disease, 71–72, 99ge, 103ge, 108ge, 300, 354ge
Hurler disease, 282
Hydatidiform mole, 198–199
Hydrops-ectopic calcification-‘moth-eaten’ (HEM), 96
Hydrops fetalis, 96, 131
Hyperbilirubinemia, 57ge
Hypercholesterolemia, 127, 171–172
Hyperimmunoglobinemia D with periodic fever
syndrome, 198
Hyperimmunoglobulin D, 54ge, 220ge
Hypermethylation, 86–87, 130
Hypermutate, 134
Hypernephroma, 282–283
Hypersurveillance, 327–329
Hypertension, 24–25, 121, 128, 136–137, 136f, 139, 158,
162, 165, 174ge, 334
Hyperthermia, 142ge, 144ge
Hypertrophic osteoarthropathy, 10ge
Hypocalciuric hypercalcemia, 284
Hypomethylating agents, 86–87, 91

I
ICD. See International Classification of Disease (ICD)
Ichthyosis, 104ge
Identification, 143ge, 160, 204, 234, 240–241, 253ge, 265,
271–277, 286, 308, 313ge, 338
Identifier, 13ge, 174ge, 253ge, 265, 355ge
IL-1-beta activation disorders, 198
Imatinib, 4, 140–141, 161, 346
Immediate cause, 37–38
Immune deficiency, 194, 222ge
syndromes, 192–193, 197, 218ge
Immunocompromised individuals, 194, 213
Immunodeficiency, 46, 72, 76, 79–80, 84, 98ge, 332–333,
352
Immunosuppressed individuals, 45
Immutability, 270–271, 273
Imprinting, 86
Inactivated x chromosome, 279
Incidental finding, 213
Inclusion bodies, 279–281
Incomplete dominance, 144ge
Indexing, 277, 281
Infectious disease, 7ge, 34, 36, 50ge, 53ge, 154, 181–190,
194–196, 202–204, 209–211, 213–214, 216, 219ge,
222ge, 231, 233–234, 251, 339, 352, 356ge
Inflammasome, 198, 200, 207
Inflammasomopathies, 198
Inflammatory disease, 54ge, 94, 139, 196–201, 220ge,
251
Inflammatory myofibroblastic tumor, 346
Inflammatory pathway, 139, 196–197, 200–201
Inflammatory response syndrome, 8ge
Information is release, 305
Informed consent, 346
Inherited dilated cardiomyopathy, 171
Inherited retinoblastomas, 313ge
Initiation, 45, 50ge, 54ge, 101ge, 145ge
Initiation factor, 56ge, 145ge
Innate immune system, 138, 197–201
Inscrutable genes, 69–78
Institutional Review Boards (IRBs), 275–276, 307, 346
Intermediate cause, 37–38
Internal body spaces, 237
International Classification of Disease (ICD), 233–234
Interoperability, 282, 306
Interpretation errors, 300
Interstitial cystitis, 206
Intracellular, 134, 190–191, 195, 199–200, 217, 220–222ge,
279
organisms, 195
Intraductal hyperplasia, 32
Intraflagellar transport, 123
Intrinsic factor, 135
Intrinsic immunity, 281
Introns, 83
Introspection, 269–270
IRBs. See Institutional Review Boards (IRBs)
Irreproducible, 6, 216, 218ge, 252ge, 298–300, 309
Irreversible, 126, 275–276
Irritable bowel syndrome, 206, 213

J
JAK2, 105ge, 139–140, 165
JAK2 mutation, 56ge, 140, 165
JAK2V617F, 140
Janus kinase, 72
Jeune chondrodysplasia syndrome, 122–123
Joubert syndrome, 122–123

K
Kallman syndrome, 98ge, 104ge
Kaposi sarcoma, 45–46, 50ge, 210–211, 293, 339
Karyopyknosis, 49ge
Karyotype, 89f, 103ge
Kashin-Beck disease, 206, 209
Kawasaki disease, 206
Kelley-Seegmiller syndrome, 105ge
Keratoacanthoma, 45, 49ge, 54ge
Kingella kingae, 203, 220ge
Klebsiella granulomatis, 217
Knockout mice, 27, 54ge, 128, 143ge, 352
Koch’s postulates, 201–205, 352, 356ge
Koilocytosis, 280f
Korean War, 286–287
Kupffer cells, 166–167

L
LAMA4 gene, 95
Lamellar inclusions, 137
Lamina propria, 203–204, 208
Lamin B receptor, 96
Lamin gene, 330–331
Large follicular center cell (diffuse histiocytic)
lymphoma, 161
Lassa fever, 219ge
Latency, 29–30, 46–47, 54ge
Lead-induced encephalopathy, 128
Leber congenital amaurosis, 122–123
Legacy data, 270, 273, 306, 314ge
Leishmaniases, 194–195, 342
Leishmaniasis, 154, 187–189, 219ge, 223ge
Leri-Weill dyschondrosteosis, 53ge
Lesch-Nyhan disease, 351–352
Lethal acantholytic epidermolysis bullosa, 70
Lethal genotypes, 144ge
Lethal junctional epidermolysis bullosa, 6, 70
Leukemia, 4, 9ge, 28, 33–35, 46, 49ge, 55–56ge, 58ge, 73, 87,
95–97, 103–104ge, 139–141, 142ge, 155–157,
160–162, 166, 233–234, 251, 339, 346, 349–350,
354ge
Lewy bodies, 126, 279
  dementia, 279
Lichen sclerosus, 206
Liddle syndrome, 24–25, 136f, 165
Li-Fraumeni syndrome, 49–50ge, 73, 103ge
Ligneous conjunctivitis, 79, 354
Limb malformation, 75, 168
Lineage, 9–10ge, 49ge, 51–52ge, 55–56ge, 84–85, 88,
100–103ge, 105ge, 107–108ge, 131, 185f, 230–232,
235, 242–243, 252–253ge, 255–257ge, 314ge, 318ge,
358ge
Lipodystrophy, 70–71, 172, 330–331
Lipopolysaccharide, 353
Liver cancer, 28, 47–48, 52ge, 159, 251, 340
LMNA (Lamin A/C), 70–71, 331
LMO2, 46
Locus heterogeneity (LOH), 71–72, 101ge, 103ge, 120, 141
Long branch attraction, 187, 221–222ge
Long noncoding RNA, 106ge
Loss-of-function, 98–99ge, 118, 158–159, 197–198
Lou Gehrig disease, 282
Louis-Bar syndrome, 99ge
Low penetrance, 27, 50ge
LRRK2 gene mutation, 164–165t, 171
LRRK2 protein kinase, 171
Lubeck disaster, 22
Lymphoma, 28, 45–47, 49–50ge, 52ge, 55ge, 88, 103ge, 139,
155–157, 161, 251, 292–293, 293f, 339–340, 346,
349–350, 356–357ge
Lymphoproliferative disease, 45, 55ge
Lymphoproliferative disorder, 50ge, 56ge
Lynch cancer family syndrome, 50ge
Lynch syndrome, 119, 143ge
Lytico-Bodig disease, 206

M
Machine translation, 255ge, 282–283
Macrophage, 23, 54ge, 137–138, 140, 195, 198–199, 201,
203–204, 220ge, 280–281, 346
activation disorders, 199
Mad hatter disease, 168
Majeed syndrome, 54ge, 198, 220ge
Major histocompatibility complex, 72
Malakoplakia, 281
Malaria, 107ge, 169, 172, 182, 184, 195–196, 215, 219ge,
223ge, 244–245
Malassezia furfur, 217
Malignant fibrous histiocytoma (MFH), 218ge, 252ge
Malignant phenotype, 28, 47–48, 50ge, 55ge, 87, 99ge,
105ge, 107ge, 175ge
Malignant transformation, 26–27, 238
Malnutrition, 219ge, 222ge
MALToma, 30, 48, 357ge
Maltomas, 49ge, 55ge
Mantle zone, 1
Manual coding, 283
Marchiafava-Bignami disease, 159
Martsolf syndrome, 175ge
Materia medica, 200
Maternal lineage, 55ge
Mathematical models, 356ge
Maturity onset diabetes of the young (MODY), 76, 96–97
Mayaro fever virus, 219ge
McKusick-Kaufman syndrome, 122–123
Meckel-Gruber syndrome, 122–123
Mediterranean anemia (thalassemia), 200
Medullary, 81, 103ge
Medullary thyroid carcinoma, 237, 255ge
Medulloblastoma, 103ge
Melanoma, 26–27, 33, 55ge, 94–95, 103–104ge, 107–108ge,
237, 288
MEN2 (multiple endocrine neoplasia-2), 256ge
Mendelian disease, 104ge, 131
Mendelian inheritance, 104ge, 131–132, 144ge, 154
Menetrier disease, 53ge
Merkel cell carcinoma, 339
Mesenchymal cells, 242–243
Mesoderm, 58ge, 60–61ge, 88, 101ge, 104ge, 158, 235–238,
242–243, 255ge
Mesothelioma, 26–27, 29, 126, 167–168, 339
Metabolic pathway, 24, 117, 120, 125, 159, 191, 235, 346,
348
Metabolic syndrome, 158, 174ge
Metadata, 264, 267–270, 286, 311ge, 316ge
Metastasis, 9ge, 144ge, 221ge, 251, 255ge
Metazoa, 230, 255ge
Methemoglobinemia, 128
Methotrexate, 128
Methylating agents, 86–87, 91
Methylation, 75, 84, 86–87, 90–91, 100–101ge, 103ge
inhibitors, 91
Methylmalonic acidemia, 128
MFH (malignant fibrous histiocytoma), 218ge, 252ge
MGUS (monoclonal gammopathy of undetermined
significance), 31, 55ge, 248–249
Microarray, 13ge, 336, 342, 357ge
Microdeletion disease, 104ge
Microphthalmia-, 53ge, 61ge, 82, 145ge
MicroRNA, 85, 91–92, 104ge, 106ge
Microsatellite, 57ge, 98ge, 143–144ge
  instability, 119, 140, 144ge
Microscopic polyangiitis, 207
Microthrombotic disorder, 125
Miller syndrome, 128
Milroy disease, 75, 96–97, 120
Mimics of common diseases, 129, 131, 248
Mimics of rare inherited disease, 131
MiRNA, 104ge
Misfolded proteins, 98ge, 144ge
Mismatch repair, 42, 51ge, 130, 140, 143–144ge
  pathway, 130
Mitochondrial DNA, 73, 77
Mitochondrial myopathy, 128
Mitochondriopathic deafness, 128
Mitochondriopathies, 84, 104ge, 164
Mitosis, 55–56ge, 109ge
Modeling algorithms, 357ge
MODY (maturity onset diabetes of the young), 76, 96–97,
121, 164–165t
Monkeypox virus, 219ge
Monoclonal gammopathy, 31, 50ge, 55ge, 248–249
Morgellons disease, 207
Mortimer disease, 207
Motor neuron disease, 104ge, 279
Muckle-Wells syndrome, 54ge, 198, 220ge
Mucolipidosis, 142ge
Muir-Torre syndrome, 50ge
Multicentric Castleman disease, 50ge
Multiclass classification, 230, 255ge
Multiclass inheritance, 50ge, 256ge
Multifactorial disease, 103ge
Multiple basal cell carcinoma, 175ge
Multiple endocrine neoplasia, 256ge
Multiple myeloma, 31, 55–56ge, 248–249, 249f
Multiple sclerosis, 197, 201, 349–350
Multipotent stem cell, 56ge
Multi-step disease, 29–30
Multistep pathogenesis, 12ge, 205
Muscular dystrophy, 53ge, 56ge, 70, 122, 175ge, 330
Muscularis propria, 265
Mutagen, 56ge
Mutation, 2, 23, 69–70, 118, 156, 187, 250, 281, 329
Mutation rate, 336, 357ge
Mutator phenotype, 156–157, 175ge
Myalgic encephalomyelitis, 346, 349–350
Myasthenia gravis, 126, 133, 142ge, 197
MYC, 47–48, 95
Myelodysplastic syndrome, 104ge, 156–157, 250
Myelofibrosis, 56ge, 139, 165
Myeloproliferative disorders, 33–34, 56ge, 60ge, 104ge,
124, 139–140, 165
Myeloproliferative syndrome, 48ge
Myofascial pain syndrome, 207
Mytotonic dystrophy, 108ge
Myxomatosis, 350–351

N
Naegleria encephalitis, 194, 213
Naegleria fowleri, 194, 213
National Academies of Sciences, 1
National patient identifier, 276–277, 314ge
Natural selection, 35–36, 41, 43, 56ge, 58ge, 157–158, 169,
191–192, 334, 336
Neonatal-onset multisystem inflammatory disease,
  54ge, 220ge
  chronic neurologic cutaneous and articular syndrome,
  198
Neorickettsia sennetsu, 210–211, 218
Nephroblastomas, 30, 243
Nephronophthisis, 122–123, 351–352
Nerve cells, 143ge
Nerve conduction, 82
Neural crest, 81–82, 84, 219ge, 235, 237–238, 254–256ge
Neural tube, 237–238
  defects, 121
Neurectoderm, 88, 105ge
Neuroblastoma, 75, 95, 155–156, 293, 346
Neurocristopathy, 238, 256ge
Neurofibrillary tangles, 126, 353
Neurofibroma, 56ge, 74–75, 313ge
Neurofibromatosis, 27, 56–57ge, 74–75, 104ge, 109ge, 138,
145ge, 256ge, 313ge, 354ge
Neuromuscular junctions, 138
Neuron, 51ge, 84, 100ge, 104ge, 107ge, 279
Neurotoxin, 300
Neutralizing autoantibodies, 137–138
Neutropenia, 49ge, 76, 83, 100ge, 133–134, 137, 197–198,
346
Nevocellular cells, 57ge
New daily persistent headache, 207
New variant creutzfeldt jakob disease, 144ge
NF-B activation disorders, 199
NKX2.5 homeobox gene, 53ge
Nodding disease, 207–209
Nomenclature, 10ge, 12ge, 38, 59ge, 61ge, 216, 221ge,
223ge, 233, 241, 257ge, 282–284
Nomenclature code, 282–283
Noncoding region, 76–77, 101ge, 106ge, 118, 127, 158–159,
336
Nonconvergent disease, 124
Nonhistone chromatin complex, 84
Nonhistone nuclear protein, 88
Non-Hodgkin lymphoma, 349–350, 357ge
Noninherited genetic disease, 33–34, 57ge
Nonphylogenetic property, 187, 222ge
Nonphylogenetic signal, 187, 222ge
Nonquantitative data, 277–279
Nonsyndromic disease, 70, 105ge
Nuclear atypia, 19–20, 55ge, 87–88, 89f, 102ge
Nuclear membrane, 41, 87–88, 109ge
Nucleoli, 41, 87–88, 89f
Null hypotheses, 106ge, 314–315ge, 318ge
NUT-1 Gene, 164–165t
NUT midline carcinoma, 250

O
Obesity, 11ge, 54ge, 72, 75, 103ge, 123, 143ge, 157–158, 162,
174ge, 337
Object oriented programming, 223ge, 254ge, 256ge,
266–267, 269, 311–312ge, 314ge
Obligate intracellular organism, 190–191, 222ge
Observational data, 349, 358ge
Odontogenic keratocyst, 170, 175ge
Off-label, 350, 358ge
Oguchi disease, 73
Oligodendroglioma, 358ge
Onchocerca volvulus, 208, 219ge
Oncocyte, 159, 176ge
Oncogene, 26–28, 34–35, 46–47, 48ge, 54ge, 57ge, 59ge,
80–81, 107ge, 143ge, 192, 222ge, 329, 357ge
Ontology, 6, 9ge, 60ge, 232, 256ge, 306, 311ge
O’nyong’nyong fever virus, 223ge
Oocyte, 11ge, 52ge, 55ge, 107ge, 155
Open access, 303
Open reading frame (ORF), 70, 105ge
Open source, 288, 290–291, 313ge
Operating system, 232, 267, 272, 288, 313ge, 317ge
Opisthokonts, 217, 241–242
Opisthorchis viverrini flatworm (fluke), 339
Opportunistic infection, 194, 205, 222ge
Oral cancer, 159
ORF (open reading frame), 70, 105ge
Orofaciodigital syndrome, 122–123
Orphan diseases, 154
Orphan drug, 160, 175ge, 345–346
Orthodisease, 354, 358ge
Ortholog, 75–76, 105ge, 354
Orthologous gene, 105ge, 351, 354, 358ge
Osteitis fibrosa cystica, 109ge
Osteoarthritis, 94, 209
deformans endemica, 209
Osteomyelitis/synovitis, 198
Osteoporosis, 168–171
pseudoglioma syndrome, 170–171
Osteosarcoma, 73, 103ge
Outcome data, 275, 290, 348–349
Outlier, 99ge, 275, 294–295, 302
Ovarian cancer, 103ge, 136–137, 344
Oxygenic photosynthesis, 191–192

P
P53, 41, 73, 95, 103ge
Palindrome, 290
Pancreatic islet, 20, 339
Pancytopenia, 49ge, 100ge, 104ge, 254ge
PAPA. See Pyogenic arthritis, pyoderma gangrenosum,
and acne (PAPA)
Papanicolaou smear, 358ge
Pap smear, 338, 358ge
Paradox, 17–25, 231–233, 246–247, 256ge
Paraganglia, 81
Paraganglial tumor, 81
Paraganglioma, 80–81, 83–84
Paralog, 105ge
Paraneoplastic syndrome, 142ge, 144ge
Paraphyly, 255ge
Parasite, 53ge, 133, 172, 182, 194–196, 215, 217, 219–220ge,
223ge, 304
Parasitic organisms, 190–191, 223ge
Parasympathetic, 135
Parent class, 8–9ge, 12ge, 189, 205, 222ge, 229–232, 252ge,
255–256ge, 267, 269, 311ge, 314ge
Pareto’s principle, 314–315ge, 318ge
Parkin knockout mice, 352
Parkinson disease, 6–7, 52ge, 54ge, 143ge, 164–165t, 171,
352–353
Paroxysmal nocturnal hemoglobinemia, 60ge
Partial lipodystrophy, 330
Partial mole, 220ge, 257ge
Partington syndrome, 53ge
Pathway, 2, 18, 69–70, 117, 159, 184, 231, 269, 341
Pathway directed treatments, 135–145, 346–347
Pathway trials, 346
Patient confidentiality, 305
PDGFR. See Platelet derived growth factor receptor
(PDGFR)
Pelger-Huet anomaly, 88, 96, 128, 355ge
Pembrolizumab, 140
Pemphigus, 132
Penetrance, 9ge, 27, 50ge, 57ge, 74, 144ge
Percolozoan encephalitis, 213
Periodic fever syndrome, 198
Pernicious anemia, 128–130, 132–133
Peroxisome biogenesis disorder, 164
Peroxisome disorder, 222ge
Personalized medicine, 2, 337
Petriellidium boydii, 216
Phakoma, 354
Pharmacogenomics, 305, 315ge
Phenocopy disease, 105ge, 125–131, 145ge, 164, 352
Phenotype, 2, 23, 71–72, 117, 156, 197–198, 235, 303, 336
Phenotypic heterogeneity, 162, 175ge
Phenylketonuria, 56ge, 160
Phenytoin embryopathy, 121–122
Pheochromocytoma, 80–81, 83
Philadelphia chromosome, 58ge
Phocomelia, 83, 128, 168
Photosynthesis, 191–192, 219ge
Phyllodes tumor, 73
Phylogenetic chronometer, 71
Phylogenetic classification, 358ge
Phylogenetics, 72, 187, 217, 221–222ge, 253ge, 278, 358ge
Phylogeny, 340, 358ge
Pigmented villonodular synovitis, 207
Pityriasis rosea, 207
PiZZ variant, 83
Placenta, 192–193, 238–240, 255ge, 258ge
Plasma cells, 31, 55–56ge, 134, 197, 218ge, 248–249, 249f
Plasminogen deficiency, 354
Plasmodium knowlesi, 215
Plasmodium vivax malaria, 172, 196
Platelet derived growth factor receptor (PDGFR), 103ge,
140
PLEC gene, 73, 123–124
Pleiotropic, 72, 76, 105ge, 332–333
Pleiotropy, 144ge
Plod2 gene (procollagen lysine dioxygenase 2), 142ge
Pneumococcal disease, 164–165t, 195
Pneumocystis, 53ge, 216–217
Point mutation, 56–57ge, 59ge, 143ge, 331, 357ge
Polyangiitis, 206–207
Polyarteritis nodosa, 207
Polycystic kidney disease, 122–123, 174ge
Polycythemia, 56ge, 83, 105ge, 139, 165
Polygenic disease, 127, 131, 144ge, 157–158, 173–174ge,
333–334
Polymorphism, 8ge, 42, 54ge, 58ge, 78–79, 97, 102ge, 106ge,
118, 134, 143–144ge, 157–158, 174ge, 195–196,
220ge, 290, 312ge
Polynucleotide repeat disorder, 108ge
Polyvinyl chloride, 166
Population of the U.S, 11ge, 107ge, 154, 291
Porphyria cutanea tarda, 57ge, 127
Posterior cortical atrophy, 207
Posterior flagellum, 241–242
Postmitotic cell, 48, 58ge, 60ge, 98ge, 234
Post translational defects, 173ge
Post translational modifications, 26, 58ge, 101ge, 164,
175ge
Post-transplant lymphoproliferative disease, 55ge
Potocki-Shaffer syndrome, 53ge
Power law, 288, 291, 314–315ge, 356–357ge
Power series, 288
Prader-Willi/Angelman syndrome, 75, 86, 103–104ge
Precancer, 31–34, 46–47, 49–51ge, 53ge, 55–56ge, 58–59ge,
87–88, 203, 338
regression, 58ge
Precancerous condition, 31, 58ge
Precision
data, 5, 263–318
diagnosis, 106ge, 215–216, 247–258, 338
medicine, 1–13, 17, 69–109, 117, 153–154, 160–162, 187,
234, 270, 285–298, 301, 327–358
taxonomy, 210–223
Preclinical trial, 352–353, 358ge
Precursor lesions, 32, 44, 248
Precursors, 32–34, 44, 89, 95, 106ge, 134, 248, 252ge,
254–255ge
Predictive analytics, 257ge, 357ge
Predictive test, 10ge, 257ge
Predictor, 257ge
Premalignancy, 59ge
Premature aging disorders, 71
Premature aging syndrome, 70, 101ge
Prevalence, 11–12ge, 24, 27, 59ge, 101ge, 131, 154, 358ge
Prevotella dentalis, 213
Primary biliary cirrhosis, 197
Primary cilia, 9ge, 123
Primary data, 307, 315ge
Primary disease, 6, 9ge, 11–12ge, 92
vs. secondary disease, 10ge
Primary effusion lymphoma, 45
Primary erythromelalgia, 10ge, 124–125
Primary host, 220ge, 223ge
Prion, 144ge, 181, 183, 187, 203, 214, 221ge, 354
Prion disease, 119, 126, 144ge, 354
Privacy vs. confidentiality, 307, 315ge
Prognosis, 2, 10ge, 95, 108ge, 250–252
Progressive neurodegenerative disorder, 71–72
Prokaryotes, 57ge, 183, 191, 213
Promoter, 46–47, 52ge, 56ge, 59ge, 100–101ge, 106ge, 219ge
Promyelocytic leukemia, 87, 161
Properties vs. classes, 257ge
Prospective clinical trial, 344, 349
Protein folding disorders, 199
Protein misfolding disorders, 198
Proto-oncogenes, 46–47, 48ge, 57ge, 59ge, 222ge
Protozoa, 59ge, 205, 213, 216–217
Protozoal infections, 258ge
Protozoans, 23, 59ge, 205, 216–217, 258ge
Proviruses, 46
Proximate cause, 13ge, 37–38, 40, 59ge
Prurigo nodularis, 207
Psammoma bodies, 126, 279
PSA value, 277
PSEN1 gene, 95
Pseudallescheria boydii, 216
Pseudallescheriosis, 216
Pseudoagouti, 86–87
Pseudoconvergent diseases, 124
Pseudodichotomy, 199, 243
Pseudogene, 85, 106ge
Pseudo-Pelger-Huet, 128
Psoriasis, 139
Psychiatric disorder, 7
PTEN gene, 102ge, 156
Public Law, 11ge, 154, 346
Pulmonary alveolar proteinosis (PAPs), 126, 133,
137–138, 346
Putative causal oncogene, 28
P value, 314ge, 358ge
Pyoderma gangrenosum, 54ge, 198, 220ge
Pyogenic arthritis, 54ge, 198, 220ge
Pyogenic arthritis, pyoderma gangrenosum, and acne
(PAPA), 198
Pyruvate dehydrogenase, 100ge

Q
Quantitative traits, 136, 334
Quaternary disease, 12ge

R
Rag1 and Rag2 recombinase, 80
Ragged red fiber myopathy, 279
Rag genes, 192–193, 218ge
Randomized control trial, 343, 348–349
Randomly occurring mutation, 98ge
Random number, 266, 296–298
Rare diseases, 4, 19, 73, 122, 153–176, 204, 248, 289, 330
  Act of 2002, 11ge, 154
Recessive polycystic kidney disease, 122–123
Recommender algorithms, 243–244, 258ge
Redundant systems, 197
Reference laboratories, 213–214
Reflection, 30, 270, 313ge
Refractory anemia, 97, 104ge
Refsum disease, 222ge
Regression, 33–34, 47, 50ge, 55–56ge, 58–59ge
Regulatory element, 9ge, 42–43, 61ge, 76, 106ge, 145ge
Reidentified record, 312ge
Relapsing polychondritis, 197
Renal angiomyolipoma, 83, 102ge, 174ge
Renal artery dysplasia, 136f
Renal cell carcinoma (RCCs), 83, 106ge, 242–243, 282–283
Renal tubular acidosis, 128
Repeatability, 26, 343
Retinal dystrophy, 120, 122–123
Retinitis, 73
pigmentosa, 8ge, 70, 73, 101ge, 107ge, 119–120, 123,
142ge, 173ge
Retrospective data, 349
Retrovirus, 46–47, 57ge, 59ge, 182, 190, 192–193, 199,
221–223ge, 339
Rett syndrome, 7, 90, 100ge
Rhabdoid tumor, 47, 60ge, 88–90, 89f, 354
Rhabdoid tumor A, 60ge
Rhabdomyosarcoma, 49ge, 103ge
Rheumatic fever, 21–22, 132–133, 203, 233–234
Rheumatoid arthritis, 131–132, 134, 139, 197, 201, 346,
349–350
Rh incompatibility disease, 131
Rickettsia, 55ge, 191, 217, 221ge
Rickettsiosis, 217
Rieger syndrome, 53ge
Risk prediction, 248, 251–252
RNA polymerase, 59ge, 106ge, 219ge
RNA silencing, 101ge
RNA splicing, 85, 98ge
RNA that might influence gene, 85
Roberts syndrome, 83, 128, 355ge
Rochalimaea quintana, 217
Rod cone dystrophy, 72
Root cause, 2, 9–10ge, 12–13ge, 24–25, 46, 51ge, 56ge, 60ge,
71, 76–79, 81, 85, 89–90, 92, 96, 117, 121, 125, 127,
129, 137, 140, 144ge, 154–155t, 158–160, 188–189,
192–193, 195, 207, 303, 341, 345, 347–348, 351–352,
355ge
Rubber and tire manufacturing industries, 166
Russell-Silver syndrome, 75, 86, 106ge

S
Sample contamination, 216, 300
Sample size, 106ge, 296, 298, 315ge
Sampling errors, 278, 300
Sampling size, 298
SAPHO syndrome (synovitis, acne, pustulosis,
  hyperostosis, and osteitis), 207
Sarcoglycan complex synthesis, 164
Sarcoglycanopathies, 164
Sarcoidosis, 54ge, 207, 220ge
Sars virus, 219ge
Schnitzler syndrome, 199
Schwannoma, 56ge, 138, 145ge
SCID. See Severe combined immunodeficiency disease
(SCID)
SCN5A gene, 95
Screening tests, 248, 257ge, 338
Scurvy, 128, 233–234
Secondary data, 11ge, 315–316ge
Secondary disease, 6, 9–12ge
Secondary HLH, 199
Secretory breast carcinoma, 250
Self-limited disease, 210
Seminoma, 156–157, 161, 175ge, 238, 255ge, 339
Senior-Loken syndrome, 122–123
Serotype, 215, 223ge
Serratia marcescens, 212
Severe combined immunodeficiency disease (SCID), 46,
72, 80, 84
SGCD gene, 95
Shagreen patches, 54ge
Shoe industry workers, 166
Short rib polydactyly, 122–123
Short stature homeobox, 53ge
Shwachman-Diamond syndrome, 24–25, 95–96
Sick building syndrome, 207
Sickle cell anemia, 119, 334, 354ge
Sickle cell disease, 50ge, 56ge, 107ge, 119, 143ge, 160, 195,
334–335, 354ge
Sideroblastic anemia, 97, 104ge, 128
Signaling pathway, 139, 170
Sign of Leser-Trelat, 144ge
Silent mutation, 106ge
Similarity scores, 282–283
Single gene disease, 70–71, 96, 105ge, 107ge
Single nucleotide polymorphism (SNP), 56ge, 78–79,
98ge, 102ge, 106–107ge, 174ge, 336
  in GWAS, 174ge
Single nucleotide variant (SNV), 106ge
Sister chromatid cohesion, 83
Situs inversus, 105ge, 124f
Sjogren’s syndrome, 207
Sleeping sickness, 187–188
Small cell carcinoma, 173ge
Small interfering RNA, 106ge
Smallpox virus, 172
Smokovia, 18–19
Smoothened, a multifuctional protein, 170
Sodium channel, 10ge, 124–125, 142ge, 165
Soma, 34, 60ge
Somatic
  mosaicism, 103ge, 107ge, 335
  mutation, 33–34, 56ge, 59–60ge, 75, 98ge, 107ge, 165,
  335–336, 357ge
Soot, 166
Speciation, 35, 105ge, 258ge
Species, 2, 8–10ge, 17, 21–22, 31–33, 35, 41–42, 49ge, 53ge,
60ge, 75–76, 104–106ge, 119–120, 142–144ge,
171–172, 181–184, 187–188, 188–189t, 190–191,
193–194, 196, 202–204, 210–211, 213–217,
219–221ge, 223ge, 230–231, 240–242, 248–249,
253ge, 255ge, 257ge, 280f, 284, 287–288, 332, 334,
351–354, 356ge, 358ge
Spherocytosis, 70
Spliceosome disease, 107ge
Spliceosome disorder, 98ge
Spondyloarthropathies, 199
Spontaneous abortions, 128, 336
Spontaneous cerebrospinal fluid leak, 207
Spontaneously regressing diseases, 59ge
Spontaneous regression, 33–34, 55ge
Spontaneous vs. sporadic, 60ge
Sporadic, 12ge, 24–25, 50ge, 60ge, 94–96, 119–120, 126, 171,
355ge
prion disease, 119
retinoblastomas, 313ge
Sporadic disease, 6, 24–25, 119, 293
  vs. phenocopy disease, 145ge
Sporozoite, 216–217
Squamous carcinoma, 33, 35, 45, 54ge, 107ge, 166, 173ge,
203
Src oncogene, 46–47
Staging, 245–246, 250–252, 258ge
Statin, 4, 171–172
Statistical anomaly, 246–247
Stem cells, 30, 49ge, 52ge, 56ge, 58ge, 60–61ge, 101ge, 105ge,
107–108ge, 166
Stickler syndrome, 70
Stiff person syndrome, 207
Stoichiometric, 40–41
Stroke, 158, 182
Subclassify, 230–231, 245
Subpopulation of cells, 59ge, 73, 88, 238, 296
Subtypes of disease, 98ge, 250, 278, 292, 348
Succinate dehydrogenase (SDHB), 80–81
Sudden infant death syndrome (SIDS), 287
Sudden unexpected death syndrome, 207
SUMO, 256ge
Superclass, 6, 8ge, 10ge, 12ge, 222ge, 232–239, 257ge, 286,
311ge
Susceptibility, 2, 7ge, 12ge, 50ge, 73, 77–78, 91, 144ge, 157,
190, 195, 212, 222ge, 251, 332–333, 351
Susceptibility gene, 12ge, 77–78, 294
SV40-like polyoma virus, 339
SV40 virus, 339
Sweating sickness, 207
Syncytin, 193
Syncytiotrophoblasts, 238
Synovial osteochondromatosis, 207
Systemic lupus erythematosus, 133–134, 197, 251, 346,
349–350

T
Taino, 189, 196
Takayasu’s arteritis, 207
Tangier disease, 127, 164
Targeted therapies, 94, 245
Tau encephalopathy, 128
Tau protein, 281, 354ge
Taxon-A, 223ge
Taxonomy, 6, 12ge, 97–98, 181–189
T cells, 46, 72, 80, 131, 161–162, 192–193, 197, 218ge, 339
Telomere, 354
Teratomas, 30, 238, 255ge
Teratomatous neoplasms, 235
Tertiary disease, 11–12ge
Thalamus, 159
Thalidomide, 128, 168
Thesaurus, 223ge
Thorotrast, 166–167
Thrombocythemia, 56ge, 98ge, 105ge, 139, 165
Thyroid carcinoma, 12ge, 169, 181–189, 210–223, 232,
240–241, 253–254ge
Ticks, 202, 223ge
Tietz syndrome, 81–82
Time stamp, 264, 266–269, 271–272, 313ge, 317ge
Timothy syndrome, 142ge
Tnf receptor associated periodic syndrome, 220ge
TNNC1 gene, 95
TNNT2 gene, 95
Torticollis, 138, 171, 207, 350
Totipotent stem cell, 56ge, 58ge, 61ge, 90–91, 235, 238,
255ge
Toxin, 9ge, 18, 20, 22–23, 29–30, 44, 94, 101ge, 105ge,
129–130, 138, 143ge, 156–157, 159, 165–166,
168–169, 171, 194–196, 207, 235, 281, 350, 353–354
Toxoplasmosis, 184, 194–195, 339
TP53 gene, 71, 73
Trachoma, 208
Trans acting, 101ge, 108ge
Transcription factor, 9ge, 42–43, 53ge, 58–59ge, 61ge, 76,
82, 101–102ge, 106ge, 118, 145ge
Transdifferentiation, 108ge
Transfected T cells, 162
Transgenic strain, 47, 76
Translational research, 141, 145ge
Translation factor, 145ge
Translocation, 48ge, 57–58ge, 87, 108–109ge, 222ge, 251
Transplacental carcinogenesis, 167, 175ge
Transposable element, 223ge
Transposon, 106ge, 190, 221ge, 223ge
Trastuzumab, 348
Trench fever, 202
Trichodynia, 207
Trigger finger, 207
Trilateral retinoblastoma, 318ge
Trinucleotide repeat disorder, 71–72, 108ge
Triple, 42, 254ge, 267, 316ge
Trophoblastic tumor, 238, 255ge
Trophozoite, 216–217
Tropical sprue, 207
Trypanosoma brucei, 187–188
TSC2 gene, 139, 174ge
Tuberculosis, 22, 27, 182, 189, 194–196, 339, 351
Tuberous sclerosis (TSC), 27, 54ge, 72, 95, 102–103ge,
138–139, 174ge, 354, 354ge
Tubers, 102ge, 138, 354
Tumor necrosis factor receptor-associated periodic
syndrome (TRAPS), 199
Tumor speciation, 35
Turner syndrome, 53ge
Type 2 diabetes mellitus, 4, 11ge, 76, 121, 157, 199, 334
Type errors, 318ge
Type II pneumocytes, 137
Tyrosine kinase, 58ge, 140–141, 161

U
Ubiquitin protein, 61ge
Ulcerative colitis, 293–294
Ultraviolet light, 77–78, 158
Unclassifiable objects, 258ge
Undiagnosed JAK2 mutation, 165
Undifferentiated tumors, 108ge
Unikonta, 186, 241–242
Uniparental disomy, 54ge, 98ge, 109ge
Uniqueness, 2, 13ge, 264–265, 272, 275, 337
Universal and perpetual, 318ge
Universally unique identifier (UUID), 265–266, 318ge
Unphagocytosed organisms, 281
Ureteric bud, 242–243
Usher Syndrome, 70, 101ge, 122–123, 175ge
U.S. Navy, 212

V
Validation, 5–7, 13ge, 125, 301–302, 316ge, 342–343,
348–349
Vanishing bone disease, 206
Vanishing white matter, 145ge
Variable expressivity, 74–76, 109ge
Vascular endothelial growth factor, 120
Vascular malformation, 99ge
Vector, 162, 202, 219ge, 223ge
VEGFC, 120
Velocardiofacial syndrome, 104ge
Ventilator tubes, 214
Verrucous carcinoma, 339
Vesicular trafficking disorders, 164, 173ge, 175ge
Vesicular transport disorder, 175ge, 281, 354
Visceral situs anomalies, 122–123
Vital signs, 44, 328–329
Vitamin B, 97, 128
V(D)J recombination units, 80
Von Hippel-Lindau disease, 109ge
Von Recklinghausen disease, 56ge, 109ge
Von Willebrand disease, 127, 135

W
Waardenburg syndrome, 53ge, 61ge, 81–82, 145ge
Warfarin embryopathy, 121–122, 128
Warthin tumor, 159, 176ge
Wegener’s syndrome, 206
Wernicke-Korsakoff syndrome, 159
West nile fever virus, 219ge
WHIM, 76
Whipple disease, 203–204, 208, 281, 356ge
Wild-type gene, 145ge
Wilms tumors, 49ge, 53ge, 73, 243
Wilson disease, 128
Wolbachia pipientis, 208, 219ge
Wolf-Hirschhorn syndrome, 53ge, 104ge
Woolly hair, 70
World Health Organization, 13ge, 182, 216, 234, 337
Wrong statistical test, 318ge

X
X chromosome, 7, 85–86, 109ge, 279, 318ge, 336
Xeroderma pigmentosum, 109ge, 354
X-linked lymphoproliferative syndrome, 199
XML (eXtended Markup Language), 264–265, 317ge

Y
Y chromosome, 102ge, 109ge, 308, 318ge, 354ge
Yellow fever virus, 219ge, 223ge

Z
Zebrafish, 195, 347–348, 351
Zika virus, 188t
Zipf distribution, 291, 292f, 314–315ge, 358ge
Zollinger-Ellison syndrome, 164–165t
Zoonosis, 5, 26, 342
Zygote, 3, 35, 51–52ge, 54ge, 85, 107ge, 335–336, 356ge

Monday, January 22, 2018

Announcement: Precision Medicine and the Reinvention of Human Disease

In January, 2018, Academic Press is publishing my latest book, Precision Medicine and the Reinvention of Human Disease

Here is the book description, from the back cover:

Despite what you may have read in the popular press and in social media, Precision Medicine is not devoted to finding unique treatments for individuals, based on analyzing their DNA. To the contrary, the goal of Precision Medicine is to find general treatments that are highly effective for large numbers of individuals who fall into precisely diagnosed groups.

We now know that every disease develops over time, through a sequence of defined biological steps, and that these steps may differ among individuals, based on genetic and environmental conditions. We are currently developing rational therapies and preventive measures, based on our precise understanding of the steps leading to the clinical expression of diseases.

Precision Medicine and the Reinvention of Human Disease explains the scientific breakthroughs that have changed the way that we understand diseases, and reveals how medical scientists are using this new knowledge to launch a medical revolution.

Key Features
  • Clarifies the foundational concepts of Precision Medicine, distinguishing this field from its predecessors such as genomics, pharmacogenetics, and personalized medicine.
  • Gathers the chief conceptual advances in the fields of genetics, pathology, and bioinformatics, and synthesizes a coherent narrative for the field of Precision Medicine.
  • Delivers its message in plain language, and in a relaxed, conversational writing style, making it easy to understand the complex subject matter.
  • Guides the reader through a coherent and logical narrative, gradually providing expertise and skills along the way.
  • Covers the importance of data sharing in Precision Medicine, and the many data-related challenges that confront this fragile new field.

Table of Contents
Preface.                                                                 

Chapter 1. Introduction: Seriously, What is Precision Medicine?                     
  Glossary
  References


Chapter 2. Redefining Disease Causality                                            
  Section 2.1 Causality and Its Paradoxes                              
  Section 2.2 Why We Are Confident that Diseases Develop in Steps                  
  Section 2.3 Cause of Death                                           
  Section 2.4 What Is a Disease Pathway?                                              
  Section 2.5 Does Single Event Pathogenesis Ever Happen?      
  Glossary
  References


Chapter 3. Genetics: Clues, Not Answers, to the Mysteries of Precision Medicine         
  Section 3.1 Inscrutable Genes                                               
  Section 3.2 Inscrutable Diseases                                            
  Section 3.3 Recursive Epigenomic/Genomic Diseases                                              
  Section 3.4 Why a Gene-based Disease Classification Is a Bad Idea           
  Glossary
  References


Chapter 4. Disease Convergence
  Section 4.1 Mechanisms of Convergence                                       
  Section 4.2 Phenocopy Diseases: Convergence Without Mutation        
  Section 4.3 The Autoantibody Phenocopies                                      
  Section 4.4 Pathway-Directed Treatments for Convergent Diseases             
  Glossary
  References


Chapter 5. The Precision of the Rare Diseases                                          
  Section 5.1 The Biological Differences Between Rare Diseases and Common Diseases   
  Section 5.2 Precision Medicine's First Benefit: Cures for Rare Diseases            
  Section 5.3 What the Rare Diseases Tell Us About the Common Diseases               
  Section 5.4 Treatments for Rare Diseases are Effective Against the Common Diseases 
  Glossary
  References


Chapter 6. Precision Organisms                                                        
  Section 6.1 Modern Taxonomy of Infectious Diseases                                    
  Section 6.2 Our Genome Is a Book Titled "The History of Human Infections"           
  Section 6.3 Inflammatory Diseases: Collateral Damage in the War on Human Infection    
  Section 6.4 Revising Koch's Postulates in the Era of Precision Diagnostics      
  Section 6.5 Diseases-in-waiting                                              
  Section 6.6 Precision Taxonomy                                               
  Glossary
  References


Chapter 7. Reinventing Diagnosis                                                  
  Section 7.1 The Principles of Classification               
  Section 7.2 Superclasses                                                     
  Section 7.3 Classifications Cannot Be Based on Similarities                       
  Section 7.4 The Horrible Consequences of Class Blending                
  Section 7.5 What Is Precision Diagnosis?                                   
  Glossary
  References


Chapter 8. Precision Data                                                              
  Section 8.1 What Are the Minimal Necessary Properties of Good Data?              
  Section 8.2 Data Identification and Data Deidentification                      
  Section 8.3 What Do We Do With Non-quantitative, Descriptive Data?    
  Section 8.4 Incredibly Simple Methods to Understand Precision Medicine Data         
  Section 8.5 Data Reanalysis: More important than the Original Data Analysis      
  Section 8.6 What Is Data Sharing, and Why Don't We Do More of It?              
  Glossary
  References


Chapter 9. The Alternate Futures of Precision Medicine                               
  Section 9.1 Hypersurveillance                           
  Section 9.2 Do It Yourself Medicine                                   
  Section 9.3 Eugenics                                          
  Section 9.4 Public Health                                                
  Section 9.5 The Data Analyst of Tomorrow                           
  Section 9.6 Fast, Cheap, Precise Clinical Trials              
  Section 9.7 Animal Experimentation                 
  Glossary
  References

Tuesday, March 29, 2016

CLASS BLENDING: Simpson's Paradox

For the past two days, we've been posting on Class Blending. Simpson's paradox is a special case that demonstrates what may happen when classes of information are blended.


Simpson's paradox is a well-known problem for statisticians. The paradox is based on the observation that findings that apply to each of two data sets may be reversed when the two data sets are combined.

One of the most famous examples of Simpson's paradox was demonstrated in the 1973 Berkeley gender bias study (1). A preliminary review of admissions data indicated that women had a lower admissions rate than men:
Men    Number of applicants.. 8,442   Percent applicants admitted.. 44%
Women  Number of applicants.. 4,321   Percent applicants admitted.. 35%
A nearly 10% difference is highly significant, but what does it mean? Was the admissions office guilty of gender bias?

A closer look at admissions department-by-department showed a very different story. Women were being admitted at higher rates than men, in almost every department. The department-by-department data seemed incompatible with the combined data.

The explanation was simple. Women tended to apply to the most popular and oversubscribed departments, such as English and History, that had a high rate of admission denials. Men tended to apply to departments that the women of 1973 avoided, such as mathematics, engineering and physics. Men tended not to apply to the high occupancy departments that women preferred. Though women had an equal footing with men in departmental admissions, the high rate of women rejections in the large, high-rejection departments, accounted for an overall lower acceptance rate for women at Berkeley.

Simpson's paradox demonstrates that data is not additive. It also shows us that data is not transitive; you cannot make inferences based on subset comparisons. For example in randomized drug trials, you cannot assume that if drug A tests better than drug B, and drug B tests better than drug C, then drug A will test better than drug C (2). When drugs are tested, even in well-designed trials, the test populations are drawn from a general population specific for the trial. When you compare results from different trials, you can never be sure whether the different sets of subjects are comparable. Each set may contain individuals whose responses to a third drug are unpredictable. Transitive inferences (i.e., if A is better than B, and B is better than C, then A is better than C), are unreliable.

- Jules Berman (copyrighted material)

key words: data science, irreproducible results, complexity, classification, ontology, ontologies, classifications, data simplification, jules j berman

Reference:

1. Bickel PJ, Hammel EA, O'Connell JW. Sex Bias in Graduate Admissions: Data from Berkeley. Science 187:398-404, 1975.

2. Baker SG, Kramer BS. The transitive fallacy for randomized trials: If A bests B and B bests C in separate trials, is A better than C? BMC Medical Research Methodology 2:13, 2002

Monday, March 28, 2016

Open for Comment

For the past several years, I've kept this blog closed to comments. Prior to that, most of the comments were thinly disguised advertisements for pharmaceuticals, and I got tired of rejecting them. For the past month or so, I've re-opened the blog for readers' comments, without announcing the change; just to check whether I'd be inundated with computer-generated promotions.

It seems that neither software agents or readers have noticed the change. So, please, if you are a human and would like to send a comment, feel free to use the comments link at the bottom of every post. Your comments will be moderated, but I intend to approve all blogs that are created by humans, and that do not promote products or services or other web sites. You are also welcome to comment on prior posts that appeared in the past month.

- Jules Berman

key words: blog, postings, comments, announcement, jules j berman

Sunday, March 27, 2016

Expunging a Blended Class: The Fall of Kingdom Protozoa

In yesterday's blog, we introduced and defined the term "Class blending". Today's blog extends this discussion by describing the most significant and most enduring class blending error to impact the natural sciences: the artifactual blending of all single cell organisms into the blended class, Protozoa.

For well over a century, biologists had a very simple way of organizing the eukaryotes (i.e., the organisms that were not bacteria, whose cells contained a nucleus) (1). Basically, the one-celled organisms were all lumped into one biological class, the protozoans (also called protists). With the exception of animals and plants, and some of the fungi (e.g., mushrooms), life on earth is unicellular. The idea of lumping every type of unicellular organism into one class, having shared properties, shared ancestry, and shared descendants, made no sense. What's more, the leading taxonomists of the nineteenth century, such as Ernst Haeckel (1834 - 1919), understood the class Protozoa was at best, a temporary grab-bag holding unrelated organisms that would eventually be split into their own classes. Well, a century passed, and complacent taxonomists preserved the Protozoan class. In the 1950s, Robert Whittaker elevated Class Protozoa as a kingdom in his broad new "Five Kingdom" classification of living organisms (2). This classification (more accurately, misclassification) persisted through the last five decades of the twentieth century.

Modern classifications, based on genetics, metabolic pathways, shared morphologic features, and evolutionary lineage, have dispensed with Class Protozoa, assigning each individual class of eukaryotes to its own hierarchical position. A simple schema demonstrates the modern classification of eukaryotes (3). Many modern taxonomists are busy improving this fluid list (vida infra), but, most significantly, Class Protozoa is nowhere to be found.
Eukaryota (organisms that have nucleated cells)
  Bikonta (2-flagella)
    Excavata
      Metamonada
      Discoba
        Euglenozoa
        Percolozoa
    Archaeplastida, from which Kingdom Plantae derives
    Chromalveolata
      Alveolata
        Apicomplexa
        Ciliophora
      Heterokontophyta
  Unikonta
    Amoebozoa
    Opisthokonta
      Choanozoa
      Animalia
      Fungi
Why is it important to expunge Class Protozoa from modern classifications of living organisms? Every class of living organism contains members that are pathogenic to other classes of organisms. To the point, most classes of organisms contain members that are pathogenic to humans, or to the organisms that humans depend on for their existence (e.g., other animals, food plants, beneficial organisms). There are way too many species of pathogens for us to develop specific drugs and techniques to control the growth of each disease-causing organism. Our only hope is to develop general treatments for classes of organisms, that share the same properties; hence the same weaknesses. For example, in theory, it's much easier to develop drugs that work on Apicomplexans that it is to develop separate drugs that work on each pathogenic species of Apicomplexan (3).

By lumping every single-celled organisms into one blended class, we have missed the opportunity to develop true class-based remedies for the most elusive disease-causing organisms on our planet. The past two decades have seen enormous progress in reclassifying the former protozoans. Unfortunately, the errors of the past are repeated in textbooks and dictionaries.

Here are three definitions of protozoa that I found on the web. Notice that these definitions don't even agree with one another. Notice that the first definition includes single celled organisms that may be free-living or parasitic. The second definition indicates that protozoans are obligate intracellular organisms. The third definition indicates that some protozoans are pathogenic in animals but omits mention of pathogenicity for other types of organisms. None of the definitions tell us that modern taxonomists have abandoned "protozoa" as a bona fide class of organisms.

from: http://www.dictionary.com/browse/protozoan
Protozoan: Any of a large group of one-celled organisms (called protists) that live in water or as parasites. Many protozoans move about by means of appendages known as cilia or flagella. Protozoans include the amoebas, flagellates, foraminiferans, and ciliates.

from: www.medicinenet.com/script/main/art.asp?articlekey=5091
Protozoa: A parasitic single-celled organism that can divide only within a host organism. For example, malaria is caused by the protozoa Plasmodium.

from: http://www.merriam-webster.com/dictionary/protozoan
Protozoan: any of a phylum or subkingdom (Protozoa) of chiefly motile and heterotrophic unicellular protists (as amoebas, trypanosomes, sporozoans, and paramecia) that are represented in almost every kind of habitat and include some pathogenic parasites of humans and domestic animals.


References:

[1] Scamardella JM. Not plants or animals: a brief history of the origin of Kingdoms Protozoa, Protista and Protoctista. Internatl Microbiol 2:207-216, 1999.

[2] Hagen JB. Five kingdoms, more or less: Robert Whittaker and the broad classification of organisms. BioScience 62:67-74, 2012.

[3] Berman JJ. Taxonomic Guide to Infectious Diseases: Understanding the Biologic Classes of Pathogenic Organisms. Academic Press, Waltham, 2012.


- Jules Berman (copyrighted material)

key words: data science, irreproducible results, complexity, classification, ontology, ontologies, protozoa, Apicomplexa, protists, protoctista,jules j berman